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ABSTRACT 
 
Twist1, a bHLH transcriptional factor, plays a critical role in mesoderm 
development. Twist1 is overexpressed in several tumor types where it has been 
shown to affect several oncogenic processes (e.g. apoptosis, senescence, 
stemness and epithelial-mesenchymal transition), but the mechanism of action of 
this embryonic transcription factor in cancer is poorly defined. In particular, the 
laboratory where I work has demonstrated that Twist1 antagonizes oncogene-
induced apoptosis and senescence at least in part by interfering with the ARF/p53 
pathway. However, we recently collected data that Twist1 interferes with p53 also 
independently of ARF. By investigating the role of Twist1 in sarcomas, we found 
that Twist1 interacts directly with p53. As a result of this interaction, Twist1 hinders 
key phosphorylations of p53, thus facilitating MDM2:p53 complex formation and p53 
degradation. Our study suggests the existence of a “Twist code” for p53 inactivation 
in sarcomas and discloses the possibility that targeting of Twist1:p53 interaction 
might provide novel therapeutic strategies for these tumors. 
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INTRODUCTION 
 
TWIST 
The Twist family of transcription factors is composed by two members, Twist1 and 
Twist2 (collectively hereafter named Twist). 
The human TWIST1 gene maps to chromosome 7q21.2 and encodes a basic helix-
loop-helix (bHLH) transcription factor. It is therefore characterized by the presence 
of a conserved domain containing a stretch of basic aminoacids adjacent to two 
amphipatic -helices separated by an inter-helical loop (Murre et al., 1989; Jan et 
al., 1993) (Fig. 1) 
 
 
 
     
 
 
 
 
Fig. 1. Representation of the molecular structure of human Twist1 protein. 
NLS1 and NLS2, nuclear localization signal sequences 1 and 2; bHLH, basic helix-loop-helix 
domain; WR, the tryptophan and arginine motif. The number of aminoacid residues for each 
structural domain is also indicated. Adapted from Qin et al., 2012.  
 
The protein is composed by 201 aminoacids with a calculated molecular mass of 
approximately 21kDa. The aminoacid sequence displays 96% identity to mouse 
twist and 100% sequence conservation in the DNA-binding region among all 
species in which it has been characterized including human, mouse, frog, 
Drosophila, leech and C. elegans.  
As homo or hetero-dimers with other HLH-containing factors, through its basic DNA 
binding motif, Twist is capable of binding E-box consensus sequences (GAATTC) 
located on the promoter of several target genes (Jan et al., 1993) (Aa 109-121). 
Furthermore, Twist is characterized by a conserved Tryptophane-Arginine (WR) 
motif, also known as the “Twist box” . This domain is located at the C-terminus 
(Bialek et al., 2004) and plays a key role in Twist protein stability (Gripp et al., 2000; 
 109-121          122-138            138-152            153-163 
NLS1 NLS2 WR bHLH 
           37- 40    73-77                                             109 -163                                 180-202 
Basic Helix I Helix II Loop 
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Demontis et al., 2006) and, possibly, in transactivation (Laursen et al., 2007). 
In order for a protein to function as a transcription factor, efficient nuclear 
localization is essential. Nuclear localization signals (NLS), by associating with 
nuclear import receptors, mediate active transport of the protein into the nucleus. H-
Twist carry a major NLS between aminoacids 37-40 (RKRR) and a second NLS 
between aminoacids 73-77 (KRGKK). These sequences are functional and may 
operate in a cooperative manner for efficient nuclear translocation. 
The closely related member of the Twist family Twist2 is located on chromosome 
2q37.3. The human and mouse Twist2 proteins are 100% identical and human 
Twist1 and Twist2 share 98% identity in the bHLH and C-terminal region. In 
particular, Twist2 is devoid of the N-terminal stretch of glycine residues that 
characterize Twist1. Twist2 is temporally expressed later in the development 
compared to Twist1 and is confined to the dermis, hence the former name Dermo 
(Wolf et al., 1991; Li et al., 1995; Lee et al., 2000) 
Besides binding E-box consensus sequences in the promoter of target genes, 
Twist1 affects gene expression also by interacting with other transcriptional 
regulators. For instance, Twist has been shown to inhibit myogenic differentiation by 
both titrating E-proteins from other myogenic bHLH transcription factors and by 
directly binding MyoD (Spicer et al., 1996; Hamamori et al., 1997). Moreover, the 
interaction between Twist1 and the general co-activators p300 or CREB-binding 
protein (CBP) results in the inhibition of transcription factors whose activity is 
modulated by these acetyltransferases (Hamamori et al., 1999).  
 
TWIST IN NORMAL TISSUES 
Twist1 was originally identified in Drosophila as a zygotic gene involved in 
mesoderm development and dorso-ventral patterning (Simpson et al., 1983; Thisse 
et al., 1987). Drosophila embryo expressing mutant TWIST alleles failed to form 
ventral furrows at gastrulation and lacked mesoderm, thus looking “twisted” 
compared to the wild-type larvae, hence the name of the gene (Thisse et al., 1988).  
Twist1 plays a key role in the formation of the mesoderm also in vertebrates. In fact, 
similar to flies, Twist null condition is lethal and Twist1 knock-out mice die for 
defects in cranial mesoderm development and failure of neural tube closure at 
embryonic day 11.5 (Chen et al., 1995). In accord with its role in mesoderm 
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generation, the expression of Twist1 is tightly regulated during embryogenesis and 
the gene is turned off as soon as mesoderm derivatives start to differentiate 
(Gitelman et al., 1997). In fact, Twist1 expression is essentially absent in adult 
mesodermal tissues. In vitro experiments indicate that a forced Twist1 expression 
correlates with a block of myoblast, osteoblast and chondroblast differentiation 
(Murray et al., 1992; Hebrok et al., 1994; Lee et al., 1999), and constitutive Twist1 
expression results in early embryonic lethality (Maestro and Hannon, unpublished), 
supporting the notion that Twist1 maintains mesodermal cells into a plastic, 
undifferentiated state.  
The repression of the muscle differentiation program is one of the best understood 
example of Twist1-mediated inhibition of differentiation. In particular, MyoD, 
myogenin, Myf5 and MRF4 (proteins belonging to myogenic bHLH subfamily) 
control the activation of muscle-specific genes through the formation of 
heterodimers with E-proteins. It has been demonstrated that Twist1 is able to 
prevent the formation of these functional heterodimers by titrating E-proteins from 
myogenic bHLH factors. Moreover, Twist1 can be also interact directly with MyoD 
and MEF2 (Myocyte Enhancer Factor 2) and this interaction results in a negative 
control of MyoD and MEF2-mediated transcription of muscle-specific target genes 
(Spicer et al., 1996; Hamamori et al., 1997; Gong et al., 2002). An involvement of 
Twist proteins are also demonstrated in the control of osteoblast differentiation 
(Zhang et al., 2008). In fact, both Twist1 and Twist2 are engaged in the modulation 
of Runx2, the master regulator of the osteogenic program (Bialek et al., 2004). In 
detail, Twist proteins can negatively regulate Runx2 function at both transcriptional 
(by promoter binding) and post-transcriptional level (by directly interacting with 
Runx2) (Yousfi et al., 2002; Bialek et al., 2004). Furthermore, recent studies 
indicate that Twist proteins participate to the control of osteogenesis by interfering 
with the Fibroblast Growth Factor (FGF) signaling pathway (Connerney et al., 2006; 
Marie et al., 2008). 
The expression of Twist factors is regulated both at transcriptional and post-
transcriptional level. For instance, Twist1 transcription is enhanced in response to 
NF-B, Wnt1, Hif factors and YB-1 (Pham et al., 2007; Howe et al., 2003; Gort et 
al., 2008; Evdokimova et al., 2009) and Twist1 mRNA turnover is regulated by 
several microRNAs, including miR-580 (Nairismägi et al., 2012) and miR-214 (Li et 
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al., 2012). Furthermore, Twist undergoes ubiquitination and proteasome-mediated 
degradation (Demontis et al., 2006) and PKA-mediated phosphorylation at Ser42 
and Ser68 facilitates Twist1 stabilization (Firulli et al., 2005; Vichalkovski et al., 
2010; Corsi et al., 2002) . 
 
 
TWIST IN CANCER 
In addition to their essential role in organogenesis, Twist proteins have been shown 
to play a relevant role in cancer. In particular, the first evidence linking Twist to 
cancer came from a genetic screen for cDNAs capable of overriding Myc-induced 
apoptosis (Maestro et al., 1999). Among the several clones isolated from the 
screen, Twist1 and Twist2 stood out as multiple independent isolates. The same 
study demonstrated that Twist1 was overexpressed in rhabdomyosarcomas, where 
it was suggested participate to transformation by both antagonizing the ARF/p53 
signaling and by inhibiting myogenic differentiation (Maestro et al., 1999). 
Subsequently, Twist1 overexpression was demonstrated in other tumor types 
including neuroblastomas (Valsesia-Wittman et al., 2004), melanomas (Hoek et al., 
2004), gliomas (Elias et al., 2005; Mikheeva et al., 2010), and different types of 
carcinomas, such as breast (Yang et al., 2004; Martin et al., 2005; Mironchik et al., 
2005; Vesuna et al., 2008; Ansieau et al., 2008; Soini et al., 2011), prostate (Kwok 
et al., 2005; Yuen et al., 2007; Pham et al., 2007), stomach (Rosivatz et al., 2002; 
Feng et al., 2009a), nasopharyngeal (Song et al., 2006; Zhang et al., 2007), 
hepatocellular (Lee et al., 2006; Niu et al., 2007; Matsuo et al., 2009), esophageal 
(Yuen et al., 2007; Sasaki et al., 2009) and lung carcinomas (Merikallio et al., 2011). 
In carcinomas, Twist1 activation has been associated to metastatic progression as 
a result of a transdifferentiation process named epithelial-mesenchymal transition 
(EMT). In these contexts, Twist1 would facilitate the loss of epithelial features and 
gain of mesenchymal traits by transcriptionally repressing the E-cadherin promoter 
(Karreth and Tuveson, 2004; Yang et al., 2004). In other contexts Twist proteins 
have been demonstrated to participate to the early phases of tumorigenesis by 
promoting the bypass of safeguard programs (oncogene-induced cell senescence 
and apoptosis) via inhibition of the INK4A locus (p14ARF and p16) (Valsesia-
Wittman, 2004; Ansieau et al., 2008; Maestro et al., 1999). Finally, Twist expression 
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has been linked to stemness, cell renewal (Isenmann et al., 2009; Yang et al., 2010; 
Morel et al., 2012) and chemo-resistance (Wang et al., 2004; Pham et al., 2007; 
Xue et al., 2012; Pai et al., 2012). Thus, Twist seems to affect cancer development 
by intersecting different oncogenic pathways. The apparent pleiotropic roles exerted 
by Twist may be reconciled by the evidence that bypass of safeguard programs, 
EMT and stemness are strictly related phenomena. In fact, recent findings indicate 
that Twist-induced EMT is likely a “side effect” of the bypass of oncogene-induced 
senescence (Ansieau et al., 2008). Moreover, the “plastic” state that characterize 
stem cells relies on the expression of a set of embryonic transcription factors 
including Twist1 (Bastid et al., 2008). 
 
 
p53  
p53 is a transcription factor that plays a central role in the control of a wide 
spectrum of biological processes and cellular stresses. In particular because its 
ability to orchestrate apoptosis, cell cycle arrest, senescence, and DNA repair p53 
has been defined “the guardian of the genome” (Lane 1992).  
p53, encoded by the TP53 gene on chromosome 17 (17p13.1) is a 393 aminoacid-
long protein composed of five separate functional domains (Fig. 2): 1) an N-terminal 
transactivation domain (TAD; residues 1-40), required for transcriptional activation; 
2) a proline-rich domain (PRD; residues 61-94) containing five PXXP motifs (P is a 
proline and X other residues) that enables protein-protein interactions (Walker & 
Levine, 1996) and participates in the regulation of p53 stability and activity (Chang 
et al., 1995); 3) a DNA-binding domain (DBD; residues 100-300) which specifically 
interacts with DNA consensus recognition elements in the promoter of target genes; 
4) a tetramerization domain (4D; residues 324-355) that facilitates the interaction of 
p53 monomers to form dimers, and then dimers to form tetramers. This quaternary 
structure is an essential requisite for the ability of p53 to regulate gene expression; 
5) a basic C-terminal domain (CTD; residues 360-393) which binds DNA 
nonspecifically and can regulate specific DNA binding by the DBD (McKinney  et al., 
2004; Weinberg et al., 2004). Moreover, a nuclear localization signal (NLS), located 
between the DBD and the 4D, and a nuclear export signal (NES), included in the 4D 
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domain, control the nuclear shuttling of the protein (Stommel et al., 1999; Toledo 
and Wahl, 2006).  
 
Unstressed cells 
  
 
 
 
 
Cellular stresses 
 
   
 
 
 
Fig. 2. Schematic representation of the molecular structure and regulation of p53 protein. 
TAD, transactivation domain (residues 1-40); PRD, proline-rich domain (residues 61-94); DBD, DNA-
binding domain (residues 100-300); NLS, nuclear localization signal sequence; 4D, tetramerization 
domain (residues 324-355); NES, nuclear export signal; CTD, C-terminal regulatory domain 
(residues 360-393). 
In unstressed cells (upper figure) the activity of p53 is regulated by MDM2 action which inhibits p53 
in two main ways: it occludes the p53 TAD domain (thereby preventing the recruitment of 
transciptional co-activators such as p300) and, through its ubiquitin ligase activity, can ubiquitylate 
p53 CTD to promote its proteasome-dependent degradation. After cellular stresses (lower figure), 
such as DNA damage, several kinases phosphorylate p53 at different residues: the phosphorylation 
of serine and threonine in the TAD and in the PRD are responsible of the reduced binding of MDM2 
to p53. These modifications leads to p53 accumulation and the formation of tetramers which are the 
fully activated form of p53. Adapted from Toledo and Wahl; 2006 
 
One of the normal function of p53 is the block of cellular progression through the 
cell cycle under conditions that could generate or perpetuate DNA damage. In 
response to these events, p53 causes primarily an arrest in the G1 phase of cell 
cycle through the induction of the cyclin-dependent kinase inhibitor p21 (Brugarolas 
et al., 1995; Deng et al., 1995). p53 can induce the growth arrest also in the G2 
phase, by affecting the nuclear localization of the cyclin B1/cdc2 complex 
(Hermeking et al., 1997; Zhan et al., 1999) by activating GADD45 (Kastan et al., 
1992) and 14-3-3(Waterman et al., 1998) and by repressing cdc25c (St Clair and 
Manfredi, 2006)
Several evidences have extensively demonstrated a critical role of p53 in the 
induction of apoptosis. In fact, p53 is involved in both the extrinsic and the intrinsic 
Ub Ub 
p53 degradation 
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4D 
NES NLS
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death pathways (Haupt et al., 2003) by inducting a number of pro-apoptotic genes 
such as Bax, Noxa, Puma and Apaf-1 (Miyashita et al., 1995; Oda et al., 2000; 
Nakano et al., 2001; Robles et al., 2001). Furthermore, by regulating the expression 
of p21 and PAI-1 (Kortlever et al., 2006), p53 is involved also in the regulation of 
premature senescence induced by genotoxic stresses (Robles and Adami, 1998; 
Schmitt et al., 2002; Han et al., 2002; Schmitt et al., 2007) or oncogene activation 
(Serrano et al., 1997). 
p53 expression is mostly modulated at post-transcriptional level. In fact, the 
aminoacid sequence of p53 contains several conserved residues, including serines, 
threonines, and lysines that have a crucial role in p53 turnover and activation 
(Brooks  et al., 2003). In particular, in unstressed cells, p53 is expressed at low level 
and inactive, mostly because of the action of the ubiquitin ligase MDM2. This 
enzyme, which is also transcriptional target of p53 itself, downmodulates p53 via 
direct interaction. This interaction results in both a steric inhibition of p53 
transcriptional activity -preventing p53 from recruiting transcriptional co-activators 
such as CREB binding protein (CBP)/p300 (Oliner et al., 1993)- and in a promotion 
of proteasome-mediated degradation consequent of MDM2 ubiquitylating  activity at 
p53 CTD (Honda et al., 1997). After stress, several kinases are activated to 
phosphorylate serines and threonines of p53 and these events eventually impair the 
binding of MDM2 to p53. The reduction of MDM2 binding leads to p53 accumulation 
and the consecutive formation of tetramers that appears critical to its ability to 
binding DNA and activate transcription (Kaku et al., 2001). The process of 
tetramerization also masks the nuclear export signal, facilitating the accumulation of 
p53 in the nuclear compartment. Although p53 accumulates preferentially in the 
nucleus, some studies suggest that following stress, a fraction of the p53 molecules 
could remain in the cytoplasm, translocates to the mitochondria and binds anti-
apoptotic BCL2 or BCL-XL to promote apoptosis through mitochondrial outer 
membrane permeabilization (Mihara et al., 2003). 
As mentioned above, MDM2 is a transcriptional target of p53. This implies that, 
reached a threshold, p53 starts to activate its negative regulator, thus establishing a 
negative  feedback loop (Momand et al., 1992; Wu et al., 1993).  
Beside DNA damage or growth factor deprivation, p53 is induced also following 
oncogene activation. In particular p14ARF, one of the two products of the INK4A 
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tumor suppressor gene together with p16INK4A, plays a central role in the 
activation of p53 response. Specifically, ARF is thought to stabilize and stimulate 
p53 activity by neutralizing the inhibitory effects of two ubiquitin ligases, MDM2 and 
ARF-BP1/Mule (ARF-binding protein1/Mcl1-ubiquitin ligase E3) (Ozenne et al., 
2010). 
 
 
p53: POST-TRANSLATIONAL MODIFICATIONS 
Several post-translational modifications, including phosphorylation, acetylation, 
glycosylation, methylation, neddylation, sumoylation, and ubiquitylation reversibly 
modify p53. Many of these modifications occur in response to stress stimuli, such as 
DNA damage, oncogene activation and growth factor deprivation, and modulate p53 
response by regulating, sometime in an opposite manner, p53 stability and 
transcriptional activity. 
For example, p53 may undergo lysine acetylation operated by CBP/p300, PCAF, 
Tip0 or hMOF acetyl transferases. These modifications results in either attenuated 
or potentiated p53 activity depending on the residue of lysine affected. In particular, 
while acetylation of lysine 320 (K320) by the p300 and CBP associated factor 
(PCAF) hampers p53 apoptotic activity (Chao et al., 2006), acetylation of K373 and 
K382 enhance p53 stability and response by blocking ubiquitylation and modulating 
the binding of p53 to DNA (Sakaguchi et al., 1998; Ito et al., 2001). p53 turnover is 
well known to be regulated by ubiquitylation operated by MDM2 but also PIRH2, 
COP1, Arf-BP1 and other ubiquitin ligases that target C-terminal p53 lysines. C-
terminal p53 lysines may also undergo neddylation (mediated by MDM2 and 
PBXO11), sumoylation (mediated by PIAS and Topors) and methylation (promoted 
by Emyd2, Set7/9, Set8, G9a/Glp, PRMT5) and these events may have different 
outcomes.  
However, p53 phosphorylation is definitively the post-translational modification most 
intensively studies. Human p53 has multiple phosphorylation sites, including several 
serines (6, 15, 20, 33, 37, 46, 315, 371, 376, 378, and 392) and three threonine 
residues (18, 55, and 81). Kinases involved in p53 phosphorylation include ATM, 
ATR, DNAPK, CK1, CK2, Chk1/Chk2, HIPK2 and p38. For instance, Serine 15 and 
Serine 20 undergo phosphorylation in response to genotoxic (ionizing radiation and 
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UV) and non genotoxic stresses by the combined action of ATM/ATR, DNAPK and 
Chk1/Chk2. These modifications enhance the interaction of p53 with transcriptional 
co-activators CBP and PCAF and reduce the ability of p53 to bind to MDM2, thus 
allowing p53 stabilization (reviewed in Kruse and Gu, 2009) 
Also phosphorylation at Serine 46, activated in response to DNA damage and 
growth factor deprivation by HIPK2 and DYRK2, plays a central role in regulating 
p53 transcriptional activity and apoptotic response. 
Much less studied is the role of phosphorylation at Serine 392. The phosphorylation 
of this residue was reported to occur preferentially in response to UV radiation, 
compared to gamma radiation, but more recent evidences indicate that Serine 392 
undergoes phosphorylation also after non genotoxic stresses and oncogene 
activation (Cox and Meek, 2010; Hupp et al., 1992; Kapoor et al., 2000; Sakaguchi 
et al., 1997; Yap et al., 2004). At the biochemical level, phosphorylation of Serine 
392 has been associated to p53 site-specific DNA binding (Hupp et al., 1992) and 
stabilization of the tetramer (Sakaguchi et al., 1997). Moreover, knock-in mice 
expressing a p53 allele impaired in the phosphorylation at Serine 389 (Serine 392 in 
human p53), due to a substitution of Serine 389 with an Alanine, show increased 
susceptibility DNA damage-induced skin carcinogenesis (Bruins et al., 2004; 
Hoogervorst et al., 2005) supporting the relevance of Serine 392 phosphorylation in 
p53 tumor suppressive functions. Recent studies suggest an involvement of Serine 
392 phosphorylation also in the modulation of gain of function activity of mutant p53. 
In fact, Yap and colleagues observed that the phosphorylation at Serine 392 
regulates the oncogenic function of mutant p53 (Yap et al., 2004). Serine 392 is 
target of phosphorylation in vitro by several kinases including CK2, PKR, Cdk7 and 
Cdk9, but the actual kinase responsible for Serine 392 phosphorylation in vivo is still 
undefined (reviewed by Appella & Anderson, 2001). 
 
p53 AND CANCER 
p53 is the one of the most intensively studied tumor suppressors. The term “tumor 
suppressor” indicates a class of genes that encode proteins involved in the negative 
control of several pathways such as cell proliferation and apoptosis. Their 
involvement in cancer is therefore the result of a “loss of function”, that is a series of 
events that impair their activity to restrain inappropriate cell growth and division, as 
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well as to stimulate cell death or senescence to keep the cells in a proper balance.  
Loss of the p53 tumor suppressor pathway contributes to the development of a 
large fraction of human cancers. Inactivating somatic TP53 mutations occur in over 
50% of the cases of lung, colorectal, ovarian, esophageal, larynx carcinomas and 
many others (Olivier et al., 2010). The majority of TP53 mutations detected in 
human tumors are missense mutations in the DNA-binding domain. These mutants 
lose the ability to transactivate, and hence to act as tumor suppressors. They 
instead retain the ability to heterodimerize, and may therefore exert dominant-
negative activity over the remaining wild-type p53 allele. The complete inactivation 
of the p53 response may be achieved also by loss of the remaining wild-type allele.  
Emerging evidences indicate that beside canonical inactivating gene mutations, 
other mechanisms may interfere with a functional p53 response. In fact, recent 
findings indicate that p53 is actually expressed in different isoforms due to 
alternative promoters, different translational initiation or splice variants. Moreover 
two new members of the p53 family have been discovered, p63 and p73, that are 
also expressed in several isoforms (Yang et al., 1998; Kaghad et al., 1997). 
Different isoforms may display opposite activities. In general, the isoforms that 
maintain the transactivation domain (TA forms) are provided of pro-apoptotic activity 
and share a large number of target genes. Viceversa, the Delta N isoforms (N), 
that lack the canonical transactivation domain, are thought to exert a dominant-
negative function towards the other members of the family (reviewed in Murray-
Zmijewski et al., 2006). Therefore, the portfolio of different isoforms of p53, p63 and 
p73 expressed by a cell generate a complex network of interactions that contribute 
to cancer development (Strano et al., 2000; Strano et al., 2002). 
The picture is further complicated by the finding that some mutations confer p53 
with exclusive biological and biochemical activities, different from those of wild-type 
p53. These mutations, known as “gain of function mutations”, are thought to 
contribute to tumor progression and aggressiveness (reviewed by Brosh and Rotter, 
2009). The gain of additional functions has been in part explained by the ability of 
these mutants to affect the activity of interacting partners. Among these we can 
remind TopB1, Pin1, PML but also the other members of the p53 family. In 
particular it has been shown that mutant but not wild type p53 interacts with p63 and 
p73, thus affecting their pathways (Di Como et al., 1999; Marin et al., 2000; 
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Gaiddon et al., 2001; Irwin et al., 2003; Strano et al., 2003). 
p53 response may be attenuated also as a result of expression of oncogenic 
proteins including the p53 ubiquitin ligase MDM2 or the E6 the high-risk human 
papillomavirus (HPV) oncoprotein (Oliner et al., 1993; Scheffner et al., 1990); 
alterations of p14ARF that regulates MDM2-mediated degradation (Zhang et al., 
1998); expression of inactivating microRNAs (Jin et al., 2011).  
However, there are tumor types, such as sarcomas, for which the mechanisms of 
p53 inactivation are still poorly understood. In fact, the frequency of TP53 mutations 
in these mesenchymal neoplasms is particularly low, especially in localized tumors, 
and the overexpression of MDM2 accounts for p53 inactivation only in a fraction of 
these tumors. On the light of these observations, the identification of other 
molecular mechanisms responsible of p53 inactivation is crucial for the 
development of more effective therapeutic approaches.  
 
 
 
SARCOMAS 
The term sarcoma identify a rare and highly heterogeneous group of aggressive 
malignancies that arise in or from bone, cartilage or connective tissues (such as 
muscle, fat, peripheral nerves and fibrous) or related tissues and are thought to 
arise from a precursor cell of mesenchymal origin. Overall sarcomas affect 
~500,000 individuals worldwide each year, with an European incidence rate of 6.4/ 
100,000/ year (Ducimetiere et al., 2011) 
Based on the presumptive tissue of origin, sarcomas are subdivided into over 50 
different histological subtypes including osteosarcomas (bone), chondrosarcomas 
(cartilage), liposarcomas (fat tissue), rhabdomyosarcomas (skeletal muscle), 
leiomyosarcomas (smooth muscle) and so on. From a molecular genetics 
perspective, they have traditionally been classified into two broad categories, simple 
karyotype sarcomas and complex karyotype sarcomas, each of which includes 
clinically diverse sarcomas.  
 
1- Complex karyotype sarcomas 
This category, that accounts for about 2/3 of all sarcomas, includes tumors 
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characterized by significant quantitative (aneuploidy) and qualitative (translocations, 
inversions, duplications, rings, etc.) chromosome aberrations. Most of adult 
sarcomas and sarcomas that develop after radiation exposure fall into this group.  
The causes of genomic instability of these tumors are largely unknown (Nakanishi 
et al., 1998; Donehower et al., 1992; Harvey et al., 1993; Kamijo et al., 1999).  
 
2- Simple karyotype sarcomas 
This category of tumors, that accounts for about 1/3 of all sarcomas and includes 
most infantile sarcomas, is characterized by near-diploid karyotypes and simple 
genetic alterations such as selective chromosome amplifications (e.g. well-
differentiated/dedifferentiated liposarcomas), specific activating gene mutations 
(GIST) and, more commonly, reciprocal translocations (e.g. myxoid liposarcoma). 
These tumor-specific reciprocal translocation events in most cases involve 
transcription factors and result in the  production of chimeric proteins with altered 
activities. For example, myxoid liposarcomas are characterized by the reciprocal 
translocation t(12;16)(q13;p11) that involves the FUS gene, encoding an RNA 
binding protein, and the CHOP gene which encodes a member of the C/EBP 
transcription factor family. The result is a FUS-CHOP chimeric protein, that is 
expressed under the control of the constitutively active FUS promoter. Similar to 
CHOP, FUS-CHOP forms dimers with members of the C/EBP transcription factor 
family and deregulates the transcription of genes involved in the control of 
differentiation and growth of pre-adipocytes (Rabbitts et al., 1994; Crozat et al., 
1993; Zinszner et al., 1994). Specific translocations can be associated to distinct 
sarcomas subtype, indicating their key role in the early phases of tumorigenesis.  
 
A common feature of sarcomas is the low frequency of TP53 mutation. In fact, 
although several evidence indicate that the p53 pathway is attenuated in these 
tumors, the vast majority of sarcomas, especially the ones carrying reciprocal 
translocations, retains wild-type p53 gene. Thus, other, still elusive genetic defects 
are likely responsible for the inactivation of the p53 pathway during sarcoma 
development (Borden et al., 2003; Taubert et al., 1998). 
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AIM OF THE STUDY 
 
The aim of this study was to address the role of Twist1 in the inhibition of the p53 
response in sarcoma development. 
Twist1 is a pleiotropic protein involved in multiple signaling pathways and biological 
phenomena. In particular Twist1 has been implicated in cancer because of its ability 
to induce EMT but also as a potential oncogene capable of promoting the bypass of 
p53-mediated cellular failsafe programs.  
Despite evidence of impaired p53 response, most sarcomas (in particular the group 
characterized by simple karyotype) retains wild-type TP53, which suggests the 
existence of alternative mechanisms of p53 inactivation.  
Our previous observations indicating that Twist1 was significantly overexpressed in 
sarcomas, support a role for this protein as an inhibitor of p53 in these tumors.
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RESULTS 
 
Twist1 overexpression accounts for p53 inactivation in sarcomas  
Preliminary data aimed at assessing the role of Twist proteins in the context of 
sarcoma development and progression, indicated that Twist1 was highly expressed 
in these tumors. In fact, immunohistochemical analyses (IHC) performed in 
collaboration with Prof. Doglioni (San Raffaele Hospital) and Prof. Dei Tos (Treviso 
Hospital) indicated that over 60% of sarcomas (115/181 cases of different histotype) 
displayed a strong nuclear accumulation of Twist1 (Fig. 3a), often associated to 
TWIST1 gene copy number gain. Twist2 was instead seldom expressed in 
sarcomas (6/84 cases analyzed). 
A possible role for Twist1 as an antagonist of p53 during sarcomagenesis was 
corroborated by xenograft experiments. In fact, similar to other mechanisms of p53 
inactivation (MDM2 overexpression or p53 silencing), also the ectopic expression of 
Twist1 turned out to be able of converting non-tumorigenic oncogene-challenged 
human mesenchymal cells (E1A/Ras BJ) into fully tumorigenic cells (Fig. 3b). 
 
a)                                                                             b)  
    
 
Fig. 3. Twist1 is overexpressed in human sarcomas and participates to transformation of 
mesenchymal cells.  
a) Representative Twist1 immunostaining in a synovial sarcoma (left) and in a leiomyosarcoma 
(right).  
b) E1A/Ras BJ are converted into tumorigenic cells by ectopic expression of Twist1. 
 
 
Mutations of TP53 are a rare event in sarcomas and several evidences indicate that 
Twist1 is able to attenuate the p53 pathway (Ansieau et al., 2008; Feng et al., 2009; 
Kwok et al., 2007; Lee and Bar-Sagi, 2010; Li et al., 2009; Maestro et al., 1999; 
Shiota et al., 2008; Stasinopoulos et al., 2005; Valsesia-Wittman et al., 2004; 
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Vichalkovski et al., 2010). On this ground, we hypothesized that the overexpression 
of Twist1 observed in sarcomas could account for p53 inactivation in these tumors. 
To probe this hypothesis we focused our attention on leiomyosarcomas (LMS). This 
sarcoma subtype was selected based on its frequency of TP53 mutations. In fact, 
among sarcomas, LMS is the subtype that displays the highest percentage of TP53 
mutations (Dei Tos et al., 1996; Hall et al., 1997). We were aware that sarcomas 
tend to gain TP53 mutations at late stages that contribute to disease progression 
(Cordon-Cardo et al., 1994). To avoid this confounding factor we sought to focus on 
localized/nonmetastatic tumors. Intriguingly, we found that Twist1 overexpression 
clustered among wild type LMS (Table 1).  
 
 
 LMS Twist + Twist - 
p=0.1009 
TP53 mutated 1 7 
TP53 wild-type 14 13 
 
Table 1. Twist1 overexpression in Leiomyosarcomas. 
 
Although the difference was not statistically significant, most LMS that expressed 
Twist1 maintained wild type TP53. Of the 8 cases carrying TP53 mutation, only 1 
case displayed a significant expression of Twist1.  
One of the most characterized alternative mechanism of p53 inactivation is the 
overexpression of MDM2, the major ubiquitin ligase for p53. Among sarcomas, 
liposarcomas (LS) display one of the highest frequency of MDM2 overexpression. In 
particular, de-differentiated (DD) and well-differentiated (WD) sarcomas (one the 
evolution of the other) carry a typical amplification of the chromosome region 12q13 
where the MDM2 gene maps. As a result of this amplification, MDM2 is typically 
overexpressed by these liposarcomas that retain wild type TP53 (Sandberg, 2004). 
Instead, the mechanism of p53 inactivation in myxoid/round cells, which do not 
overexpress MDM2 but retain wild type TP53, remains unclear.  
Intriguingly, when we compared the pattern of reactivity for Twist1 in a series of 
lipomatous tumors we observed that Twist1 accumulation co-segregated in a 
statistically significant manner, with the MDM2-negative variant, namely the myxoid 
subtype (Table 2). 
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 LS Twist + Twist - 
p=0.00049 
MDM2+ (WD and DD LS) 2 8 
MDM2- (Myxoid LS) 13 1 
 
Table 2. Twist1 overexpression in Liposarcomas 
 
Thus, the clustering of Twist1 overexpression in tumors that were TP53 wild type 
and negative for MDM2 overexpression supports the notion that Twist1 plays a role 
as an alternative mechanism of attenuation of the p53 response in sarcomas.  
 
 
Twist1 enhances MDM2-mediated degradation of p53 
Based on this evidence from IHC, we selected a series of human sarcoma cell lines 
in which TP53 was maintained in wild type status. As a first step we characterized 
these cell lines for the expression of Twist proteins (Twist1 and Twist2), p53 and 
MDM2 by immunoblot analyses (Fig. 4). 
In agreement with IHC data, 7/11 cell lines analyzed expressed Twist1 at detectable 
levels. Expression of Twist2 was detected only in human primary fibroblasts 
transformed in vitro by Ras and E1A (RE-BJ) and weakly in SJSA cells, an 
osteosarcoma cell line carrying amplification of MDM2. 
Based on these information, these cells were genetically manipulated in a way that 
Twist1-positive cells were downregulated by either stable expression of Twist1-
specific shRNA (Ansieau et al., 2008; Yang et al., 2004) or validated siRNA 
(Dharmacon), while Twist1 was ectopically expressed in Twist1-negative cells. 
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Fig. 4. Expression levels of endogenous Twist1, Twist2, p53 and MDM2 in RE-BJ and in the 
sarcoma cell lines used in this study. The first 6 cell lines retain wild-type TP53. SAOS-2 are p53 
null. SK-UT-1 carry bi-allelic p53 mutations (compound heterozygote for R248Q and R175H) that 
account for p53 protein stabilization. SJSA carry an amplification of the MDM2 locus. RE-BJ are 
human primary fibroblasts transformed by the ectopic expression of HRasV12 and E1A. As a 
reference control the p53-proficient HCT116 colon carcinoma cells were used (Ctr). Twist1 was 
expressed in WE-68 and Sal-1 (Ewing sarcomas), HT-1080 (fibrosarcoma), SAOS-2 and SJSA 
(osteosarcomas), SK-UT-1 (leiomyosarcoma), and RE-BJ fibroblasts. U2-OS (osteosarcoma), MES-
SA (uterine sarcoma) and VA-ES-BJ (epithelioid sarcoma) were negative for Twist1 expression.  
Twist2 expression signal was detected in RE-BJ and, after long exposure, in SJSA. Protein levels 
were normalized to GAPDH. 
 
The analysis of these cellular models revealed that modulation of Twist1 expression 
inversely correlated with expression of p53. In particular, silencing of Twist1 
correlated with an increased levels of p53 (Fig. 5). 
 
 
 
 
 
 
 
Fig. 5. Expression levels of p53 after downmodulation of endogenous Twist1 by either shRNA (left 
panel) or siRNA (right panel). p53 wild-type HT-1080, Sal-1, WE68 sarcoma cells and E1A/Ras-
transformed BJ human primary fibroblasts silenced for Twist1 expression displayed an induction of 
p53 expression. As a control (Ctr), shLuc and nontargeting siRNA pool were used. Protein levels 
were normalized to GAPDH. 
 
Conversely, ectopic expression of Twist1 associated with reduction of p53 protein 
levels (in the absence of variation of mRNA levels, data not shown). This effect was 
reversed by the treatment with the proteasome inhibitor MG132, suggesting that 
Twist1 was likely affecting p53 expression levels by impinging on p53 turnover (Fig. 
6). 
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Fig. 6. Immunoblot of two different sarcoma cell lines enginereed to ectopically express Twist1 (Tw) 
or GFP, as a control (Ctr). Cells were exposed to MG132 (10µM) or vehicle (DMSO) for 4hr, then 
harvested. 
 
 
 
This hypothesis was corroborated by the finding that the p53 half-life was increased 
in Twist1-silenced HT-1080 cells, whereas it was reduced in VA-ES-BJ expressing 
ectopic Twist1, as assessed by cycloheximide-chase (CHX) experiments (Fig. 7). 
 
 
 
 
 
 
 
 
 
Fig. 7. Cycloheximide-chase assays (CHX, 100µg/ml) in Twist1-silenced HT1080 and VA-ES BJ 
enginereed to express ectopic Twist1. The modulation of Twist1 expression affects p53 stability: 
both cell lines were treated with CHX and harvested at indicated time. shGFP (shCtr) or empty 
vector (Ctr) were used as controls, respectively.  
 
Twist1-induced degradation of p53 seems to rely at least in part on MDM2. In fact, 
after ectopic co-expression by transfection of Twist1 together with p53, we observed 
a slight but consistent reduction in p53 levels (30%) in MDM2-proficient (p53-/-) but 
not in MDM2-deficient (p53-/-; MDM2-/-) mouse embryo fibroblasts (MEF) null for 
endogenous p53. Furthermore, the increase in overall levels of p53 detected on 
Twist1-silenced HT-1080 correlated with a slight (∼30%) but consistent decrease in 
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the amount of MDM2 co-immunoprecipitated with p53. These effects underlined the 
relevance of MDM2 in the downregulation of p53 induced by Twist1 (Fig. 8) 
 
      
                     
 
 
Fig. 8. MDM2 plays a role in Twist1-induced downregulation of p53. Left panel. Immunoblot of p53-/- 
and p53-/-; MDM2-/- MEF cotrasfected with ectopic p53 and either myc-Twist1 (Tw) or empty vector 
as control (Ctr). GFP was used as a control of transfection. The levels of p53 expression (ect. p53) 
were corrected for transfection efficiency (p53/GFP ratio). Right panel.  HT-1080 fibrosarcoma cells 
were silenced for Twist1 expression, treated with MG132 10M for 8 hr and after immunoprecipitated 
for endogenous p53. Lysates were immunoblotted for p53 and MDM2 and the amount of co-
immunoprecipitated MDM2 was calculated as MDM2/p53 ratio. The panel shows a representative 
experiment of three immunoprecipitation conducted with two different antibodies (DO-1 and CM5)   
 
 
 
Silencing of Twist1 activates a p53 response in sarcoma cells 
We then investigated the biological effects of modulation of Twist1 expression. We 
observed that depletion of Twist1 expression correlated with impaired cell growth 
capability. In fact the doubling time of Twist1-depleted cells was longer compared to 
control (Fig. 9).  
 
                                
 
Fig. 9. Twist1 downmodulation correlates with impaired cell growth capability. 
The doubling time of HT-1080 Twist1-silenced cells (shTw) (evaluated by trypan blue exclusion 
assay) was ~1,2 time compared to control (shCtr). 
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Additionally, Twist1 knockdown was associated with induction of acidic β-
galactosidase activity (SA-β-gal) particularly in Sal-1 cells, suggesting a 
spontaneous premature senescence. Furthermore, in HT-1080 both genotoxic (UV, 
20 J/m2) and non-genotoxic treatments (growth factor deprivation for 48-72 hr) 
resulted in enhanced apoptosis and senescence in Twist1-depleted cells. These 
effects were paralleled by induction of p53 and p53 target genes, in particular Bax 
and Puma, and were reversed by concomitant silencing of p53 (shTw1+shp53) (Fig. 
10) 
 
a)                                                                                  b) 
 
 
  
 
 
 
       
                
c) 
 
 
 
 
 
 
 
Fig. 10. Twist1-depleted sarcoma cells are more sensitive to stress condition. 
a-b) Twist1 downregulation sensitizes HT-1080 cells to genotoxic and non-genotoxic stresses. 
HT-1080 engineered to express either shTwist1 (shTw1) or shLuciferase (shCtr) were seeded 
overnight and then either UV irradiated (20 J/m2) or shifted to serum-free medium. 
a) Photographs were taken at 24 hr and 72 hr post-stress induction, respectively. SA--gal staining 
was performed after growth factor deprivation (48 hr). 
b) Cells were seeded overnight and then were shifted to serum-free medium. Cell viability was 
assessed 48 hr after starvation. Histograms represent mean values plus SD. 
c) Sensitization to stress induced by Twist1 depletion was partially reverted by concomitant silencing 
of p53. HT-1080 cells engineered to silencing endogenous Twist1 (shTw1) and/or p53 
(shTw1+shp53) were serum starved and immunoblotted for pro-apoptotic genes Bax, Puma and 
p21. 
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Twist1 and p53 interacts directly through their C-termini 
Results from our and other groups indicated that Twist is capable of interfering with 
the p53 response by inhibiting ARF transcription (Maestro et al., 1999; Ansieau et 
al., 2008; Valsesia-Wittman et al., 2004). Nevertheless, most cell lines used in the 
experiments reported above (including HT-1080, Sal1, MES-SA, VA-ES-BJ, WE-68) 
are deficient for INK4A/ARF and we had collected evidence that Twist mutants 
defective for DNA binding domain (basic domain mutants) were still capable of 
affecting p53 levels. Overall these data indicated that Twist1 affects p53 response 
also through an ARF-independent route. It had been suggested that Twist, by 
hijacking p300/CBP, may affect p53 by interfering with p300/BCP-mediated 
acetylation. However, our previous results indicated that also Twist mutants 
deficient for p300/CBP binding were capable of interfering with p53, ruling out a 
major role for this phenomenon on p53 inhibition. Thus, we hypothesized that Twist 
could hamper p53 through direct binding. In fact, several evidences collected over 
the time by the laboratory supported this hypothesis. By co-immunoprecipitation 
experiments in sarcoma cells  we demonstrated that endogenous Twist1 bound 
endogenous p53, and in vitro experiments indicated that recombinant p53 bound 
recombinant Twist1. These results corroborated the notion that these two proteins 
did interact in vivo and that the interaction was direct (Fig. 11). 
                 
  
 
Fig. 11. Twist1 interacts with p53 both in vivo and in vitro. 
a) Cell lysates from HT-1080, SK-UT-1 and ER-MEF were incubated with either Twist1 monoclonal 
antibody (Twist1) or nonimmune IgG (Mock), immunoprecipitated and then blotted for coprecipitated 
p53 using anti-p53 antibodies. Twist1-negative MCF7 cells were used as a negative control. Input 
represents 10% of the whole cell lysate prior immunoprecipitation. 
b) Left panel: 35S-labeled in vitro translated p53 (IVT-p53) was incubated with equivalent amounts of 
GST-Twist1 or GST, used as a negative control. Complexes were visualized by autoradiography. 
Right panel: recombinant His-p53 was incubated with equal amounts of glutathione agarose-bound 
GST or GST-Twist1. After SDS-PAGE, complexes were detected with anti-GST and anti-His 
antibodies.  
 
a) b) 
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Moreover, by both GST pull-down and co-immunoprecipitation experiments the 
interaction region of Twist1 was mapped to a stretch of 20 aminoacids, 
corresponding to the highly conserved C-terminal region named Twist box (Aa 175 
to 194) (Bialek et al., 2004) while the region of p53 engaged in the interaction was 
mapped to its C-terminal regulatory region (Aa 354-393, p53CTD) (Fig. 12).  
The Twist box was key for Twist1-mediated inhibition of p53. In fact, a mutant 
deleted in the Twist box (Δ175-194) was defective for p53 binding and it lost the 
ability to antagonize p53 dependent transcription and apoptosis. Intriguingly, the 
Twist box is a domain conserved also in Twist2 and, accordingly, similar to Twist1, 
Twist2 displayed the capability of antagonizing p53 dependent transcription and 
apoptosis (Fig. 12).     
 
        
            
             
 
  
 
 
Fig. 12. Twist1 and p53 establish tail-tail interaction that involved the Twist-box domain and p53 C-
terminal regulatory domain. 
Based on GST pull-down experiments, schematic representations of the mouse Twist (upper panel) 
and human p53 (low panel) with respectively various mutants (left) and summary of their ability to 
interact (right). 
The figure shows also the relevance of an intact Twist box to antagonize p53-mediated apoptosis 
(after treatment with pro-apoptotic agent) and transcription (tested with a Dual Luciferase Assay). 
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To gain insight on the possible mechanisms of inhibition of Twist on p53, in the 
absence of crystallographic data on Twist1, we sought to take advantage of in silico 
modelling. Thus, in collaboration with Dr. Rosano of the IST (Genova), docking 
simulation analysis were conducted and associated to GST pull-down experiments. 
In silico prediction of protein:protein interaction confirmed the relevance of Twist box 
and p53CTD in Twist:p53 interaction and single aminoacid substitutions in the Twist 
box affected Twist capability to bind p53 in vitro (Fig. 13). 
       
a) 
 
   
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
Fig. 13. The Twist box is necessary for the interaction with p53 
a) Left panel: Ribbon representation of the interaction between p53 (red) and Twist1 (blue). The 
arrows indicates the Twist box:p53 interface. Right panel: Residues and their functional groups of 
human Twist1 and human p53 involved in the interaction. The table reports also the distance (in A) 
between the corresponding interacting functional groups as assessed by docking simulation. 
b) GST or GST-p53 pull-downs of IVT-Twist box or IVT-Twist box carrying the indicated aminoacid 
substitutions.   
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Twist1 interferes with p53 phosphorylation at Serine 392 
The p53 CTD plays a key role in the conversion of p53 from the latent/low-level 
form present under basal conditions to the active/stable form induced after cellular 
and genotoxic stresses. In particular, acetylation, phosphorylation, ubiquitination or 
sumoylation of C-terminal residues are involved in the regulation of p53 activity and 
stability (Xu, 2003). Serine 392 (Ser392) is one of the most conserved p53 residues. 
Several kinases have been reported to be able to target Ser392 in vitro, but it is still 
unclear what enzyme physiologically catalyzes Ser392 phosphorylation in vivo (Xu, 
2003). Furthermore, despite the numerous evidence of the importance of Ser392 in 
modulating the p53 response, the actual mechanism by which this modification 
affects p53 function is largely unknown. Phosphorylation of p53 at Ser392 (Ser389 
in mouse) has been reported to take place following different stresses, including UV 
-but not gamma- radiation, oncogene activation, growth factor deprivation and 
oxidative damage. This modification is known to stabilize tetramer formation and 
activate p53 site-specific DNA binding (Hupp et al., 1992; Kapoor et al., 2000; 
Nichols and Matthews, 2002; Sakaguchi et al., 1997; Yap et al., 2004). Moreover, it 
has been reported that Ser392 phosphorylation, rather than N-terminal 
phosphorylations, is key for the activation of oncogene-induced p53 response, and 
mice expressing a constitutively dephosphorylated p53 allele (S389A) show delayed 
p53 response and increased sensitivity to chemical and UV-induced 
carcinogenesis, pointing at the critical role of this phosphorylation site for p53 tumor 
suppressive functions (Bruins et al., 2004; Cox and Meek, 2010; Hoogervorst et al., 
2005; Jackson et al., 2004; Yap et al., 2004).  
Our docking simulations indicated that in the Twist1:p53 complex the Twist box 
sterically hinders p53CTD and in particular p53 Ser392 establishes hydrogen bonds 
with Arginine 191(Arg191) and Alanine 200 (Ala200) of Twist1 (Fig. 14)  
On these ground, we hypothesized that Twist1 could directly affect p53 by inhibiting 
Serine 392 phosphorylation. 
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Fig. 14. Magnification of the ribbon representation of Twist box (yellow):p53 CTD (fuchsia) 
interaction. 
 
 
To investigate this possibility, we verified the effect of modulation of Twist1 
expression on the status of p53 phosphorylation at Ser392 . We found that under 
basal conditions, silencing of Twist1 or ectopic Twist1 expression correlated with 
increased or decreased amount of p53 phosphorylated at Ser392, respectively. 
These effects were dependent on the capability of Twist1 to bind p53 as the ectopic 
expression of Twist box-deficient mutants (156X, 175-194) failed to significantly 
affect the fraction of phospho Ser-392 p53 (Fig. 15).  
            
 
Fig. 15. Twist1 hinders phosphorylation of p53 at Serine 392. 
Immunoblot for p53 phosphorylated at Serine 392 (P Ser392) of different sarcoma cells silenced for 
Twist1 expression (left) or engineered to express ectopic Twist1 or Twist1 mutant (right). Because 
modulation of Twist1 expression affects p53 expression levels, to better appreciate the effect of 
Twist1 on Serine 392 phosphorylation, samples are unevenly load to tentatively equalize the signal 
for total p53.  
 
 
The specificity of Twist action on Ser392 was substantiated by the finding that other 
residues included in the region of p53 engaged in the interaction with Twist and 
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target of post-translational modifications, namely Lysine 373 and 382, were not 
significantly affected by modulation of Twist expression. In particular, Twist1 
impacted only marginally on the Lysine 382 acetylation and failed to affect at all 
Lysine 373 acetylation (Fig. 16).  
Moreover, different from acetylation of these lysines, phosphorylation of Ser392 was 
significantly increased in oncogene challenged cells, indicating that the 
phosphorylation of this residue is likely to play an important role in the induction of 
p53 response after oncogene activation. 
 
                                          
        
                                           
 
                                           
                          
Fig. 16. p53 phosphorylation at Ser392 is influenced by both oncogene activation and modulation 
of Twist1 expression. Oncogene activation in BJ human primary fibroblasts (RE-BJ) results in p53 
stabilization that is paralleled by a concordant increase in the phosphorylation at Ser392 (a). 
Oncogene activation fails instead to affect acetylation at Lys 382 (b) and Lys 373 (c). Silencing of 
Twist1 in HT-1080 and Sal-1 and ectopic Twist1 expression in MES-SA were associated with 
modulation in overall p53 levels. Coherent variations were observed for the phosphorylation at 
Ser392 (a). Acetylation of Lys382 was essentially unaffected by modulation of Twist1 expression (b). 
No meaningful signal for acetylated Lys373 was detected in any cell line analyzed but in control 
TSA/adriamycin–treated MCF7 cells (+) (c). Ratios represent the amount of p53 modified at the 
residue indicated over total p53.  
a) 
b) 
c) 
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Ser392 phosphorylation status affects p53 stability and activity 
Overall, the data collected so far suggest a model where Twist1, by preventing 
Ser392 phosphorylation, impinges on the p53 response. To corroborate this model 
we asked whether Ser392 phosphorylation actually affected p53 stability and 
activity.  
We then generated mutants in which serine 392 was substituted with either an 
alanine (p53-S392A) or a glutamate (S392E), producing thus a phosphorylation-
deficient and a phosphorylation mimicking mutant, respectively.  
Cycloheximide-chase experiments in p53-negative SAOS-2 and HCT116 cells 
engineered to stably express these p53 mutants indicated that the constitutive 
phosphorylation at Ser392 increased the stability of p53. In fact, p53-S392E 
displayed a longer half-life compared to wild type p53 (p53 WT) and to the 
phosphorylation-deficient p53-S392A mutant (Fig. 17a). Since MDM2 is the major 
actor involved in the regulation of p53 turnover, we then asked whether ser392 
phosphorylation status could impinge on p53:MDM2 interaction. Co-
immunoprecipitation experiments performed in the same cellular context of previous 
experiment (p53 negative HCT116 and SAOS cells engineered to express the 
different p53 Ser392 mutants), substantiated this hypothesis. In fact, p53-S392E 
bound MDM2 less efficiently then p53-S392A or p53 WT (Fig. 17b), indicating that 
the phosphorylation at Serine 392 reduces the affinity of p53 to MDM2 and hence to 
MDM2-mediated degradation. Thus, the phosphorylation status at Ser392 
participates to the regulation of p53 stability. 
 
a)                                                                                  b) 
 
 
 
 
 
 
 
Fig. 17. Phosphorylation at Serine 392 affects p53 stability and its interaction with MDM2.  
a) Immunoblot of cycloheximide-chase assay (CHX, 250 g/ml) in SAOS-2 infected with retroviral 
vectors encoding p53 wt, p53-S392E (phospho-mimic), or p53-S392A (phospho-impaired). 
b) After retroviral infection with p53 wt, S392A and S392E mutants, SAOS-2 cells were treated with 
MG132 (10M, 8 hr) and then immunoprecipitated for p53. Immunoblots were probed for MDM2 and 
p53 and the amount of MDM2 bound to p53 was calculated as MDM2/p53 ratio. 
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Twist affects p53 stability by a dual mechanism  
These results were in line with our hypothesis that by interfering with Ser392 
phosphorylation Twist1 could impinge on p53 stability and hence p53 activity. 
Accordingly, Twist1 efficiently reduced the levels of ectopic wild type p53 (p53 WT) 
while it was unable to interfere with the stability of p53 alleles mutated at Ser392. 
Moreover, reporter assays indicated that Twist1 efficiently inhibited p53-dependent 
transcription triggered by wild type p53, while displayed impaired inhibitory activity 
toward p53 Ser392 mutants (Fig. 18). 
 
a)                                                              b) 
 
 
 
 
              
 
  
Fig. 18. Twist1 displays a reduced ability to repress p53-dependent degradation and transcription 
driven by p53 mutants carrying aminoacid substitutions at codon 392 (S392E and S392A).  
a) Immunoblot of Twist1 negative HCT116 p53-/- transfected with p53 wild type or p53 mutants as 
indicated together with either myc-Twist1 (Tw) or empty control vector (Ctr). GFP was included for 
transfection efficiency normalization. 
b) HCT116 p53-/- cells were transfected with vectors encoding the p53 alleles indicated (wild-type, 
S392E or S392A) in the presence of PG13-Luc (p53-reponsive reporter), Renilla reporter (for internal 
normalization) and either empty vector (Ctr) or myc Twist1. Dual Luciferase Assay (Promega) was 
performed and Promoter activity values are expressed as relative luciferase units (RLU) using empty 
vector-transfected cells (Ctr) as a reference (100%) for each p53 allele. The figure shows a 
representative experiment and standard deviations of the triplicates. 
 
Moreover, although it is still debated what kinase operates the phosphorylation of 
Ser392 in vivo, casein kinase 2 (CK2) has been reported to catalyze the 
phosphorylation of this p53 residue in vitro (Cox and Meek, 2010). On this ground, 
we performed a casein kinase 2 (CK2)-induced in vitro phosphorylation assay and 
we found that phosphorylation of p53 at Ser392 was attenuated in a dose-
dependent manner in presence of recombinant Twist1 (Fig. 19). 
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Fig. 19. Casein kinase 2 (CK2)-induced in vitro phosphorylation of p53 at Serine 392 is attenuated in 
a dose-dependent manner in the presence of recombinant Twist1. 
GST-only or GST-Twist1 (0.25, 0.5, 1.0 g) were incubated together with recombinant His-p53 in the 
presence of CK2. Reactions were resolved by SDS-PAGE and then probed with anti-phospho 
Ser392, anti-p53 and anti-GST antibodies, consecutively. 
 
We then asked how all these results fit with the state of the art on p53. As 
previously mentioned, it is well known that MDM2 is the major ubiquitin ligase for 
p53. It is also known that MDM2 interacts with the N-terminus of p53 and that 
phosphorylation of p53 residues implicated directly or indirectly in this interaction, 
namely Ser15 and Ser20, disturbs MDM2:p53 complex formation. Nevertheless, 
beside this canonical p53-MDM2 interaction scheme, Prive’s group has recently 
described that p53 engages also the CTD to interact with MDM2 and that post-
transcriptional modifications of p53 CTD, namely acetylations, affects p53 affinity to 
MDM2 (Poyurovsky et al., 2010). The authors conclude that other p53 CTD post-
translational modifications may affect p53 affinity to MDM2 as well. Indeed, our 
results on Ser392 phosphorylation are in line with this hypothesis. Thus, the data 
collected so far are compatible with a scenario where Twist, by impeding Ser392 
phosphorylation, maintain p53 CTD in an state suitable to the binding to MDM2 and 
hence to the alternative route of MDM2-mediated degradation. 
Nevertheless, Prive’s group have shown that the interaction between p53CTD and 
MDM2 in turns affect also the canonical interaction between N-terminus p53 and 
MDM2 and Lozano’s group has suggested an interplay between Ser392 and Ser15 
(Kapoor et al., 2000). On this ground we investigated whether Twist1, by acting on 
Ser392, was actually affecting also Ser15 status. Intriguingly, we found that the 
phosporylation at Ser392 resulted in an increased phosphorylation at Ser15, but not 
vice versa. In fact, a constitutively phospho-mimic p53 allele (Ser392E) displayed a 
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greater extent of phosphorylation at Ser15 compared to the phospho-impaired 
mutant (S392A)(Fig. 20a), both in normal condition and after genotoxic (UV 
treatment) and non-genotoxic (serum deprivation) stresses. Instead, a Ser15 
constitutive phosphorylation allele (S15E) failed to display any difference in the 
extent of phosphorylation at Ser392, compared to the unphosphorylated S15A allele 
(Fig. 20b). 
 
a)                                                          b) 
 
 
 
 
 
 
 
Fig. 20. Phosphorylation of Serine 392 controls Serine 15 phosphorylation status. 
a) Immunoblots of HCT116 p53-/- engineered to express either p53-S392A or p53-S392E mutants 
for phosphorylation status at Serine 15 of p53, under standard condition (NT), UV radiation (20J/m2) 
or serum starvation (30 hr) 
b) Western blot of HCT116 engineered to express either p53 wild-type, S15A (Ser15 phospho-
deficient) or S15E (Ser15 phospho-mimic) mutants, under standard culture conditions (NT), UV 
radiation (20J/m2) or growth factor deprivation (30 hr). Irrespective of Ser15 status, all alleles 
displayed a similar degree of phosphorylation at Ser392. Similar effects were seen in analogously 
engineered SAOS-2 cells. 
 
These results suggested that by interfering with the phosphorylation at Ser392, 
Twist in turn affected also the phosphorylation at Ser15 (Fig. 21).  
 
                
 
Fig. 21. Proposed mechanism of Twist action on p53 phosphorylation status. 
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Indeed, we observed that p53 underwent coherent variation in the extent of 
phosphorylation at Ser392 and at Ser15 after either silencing or ectopic expression 
of Twist1 in sarcoma cell lines (Fig. 22).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 22. Twist1 expression affects p53 phosphorylation at Serine 392 and 15. 
Different sarcoma cell lines were engineered to upregulate (MES-SA) or downregulate  HT-1080 and 
Sal-1 Twist1 expression. Cell lysates were immunoblotted for p53 phosphorylation at Serine 392 and 
Serine 15 and GAPDH was used for loading control. Variations of Serine 392 and 15 
phosphorylation correlated with modulation of Twist1 expression.  
 
Overall, our data strongly support the notion that Twist1, by interfering with key 
phosphorylations, participate to the attenuation of the p53 response during 
tumorigenesis. 
Intriguingly, we found that Twist1 was transcriptionally upregulated in human 
primary cells following oncogene challenging, namely human primary BJ fibroblasts 
engineered to ectopically express either E1A or E1A and Ras (Fig. 23). 
                                                                                                                                                                                                            
                
                                              
 
 
Fig. 23. Twist1 is induced in response to oncogenic pathways (E1A and E1A/Ras) in BJ human 
fibroblasts. These results was confirmed in 3 independent infections. Ctr represents empty vectors-
infected cells. Relative mRNA levels (right panel), in which the first sample was arbitrarily set as 1, 
are reported as results of RT-PCR in which expression of CFL1, GAPDH and -actin were used as 
housekeeping genes. The figure shows the average and standard deviations of three independent 
RT-PCRs. 
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This result discloses a scenario where the activation of Twist1 would allow 
oncogene-challenge cells to attenuate p53 response during transformation. In 
particular, oncogene activation would unleash a full p53 response that typically 
triggers apoptosis, senescence and growth arrest. The concomitant activation of 
Twist in suitable cell contexts, by acting on both the ARF pathway and by directly 
affecting key phosphorylations of p53, would attenuate these failsafe programs thus 
allowing oncogenes to exert their transforming potential (Fig. 24). 
 
  
           
   
Fig. 24. Schematic representation of the proposed mechanisms of Twist1 contribution to oncogene-
induced transformation and attenuation of p53 response. 
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DISCUSSION 
 
An increasing body of data indicates that Twist proteins play an important role in 
tumorigenesis but their actual mechanism of action as oncogenic factors is not fully 
understood. This study provides evidence that Twist proteins promote MDM2-
mediated degradation of p53 by directly interacting with its C-terminal regulatory 
domain and by physically interfering with key phosphorylations, unveiling an 
unprecedented mechanism of inactivation of p53. 
Given the complexity of the Twist network, to better unravel the oncogenic function 
of Twist, and in particular its role as an antagonist of the p53 response, we sought 
to focus on sarcomas for three main reasons: a large fraction of these tumors 
retains wild-type p53 but the mechanisms of inactivation of the p53 response are 
still elusive; being mesenchymal in nature, sarcomas offer the opportunity to discern 
the functions of Twist related to the induction of EMT, typically occurring in 
carcinomas, from those more specifically related to the interference with tumor 
suppressive pathways; accumulation of Twist1 had been reported in sarcomas and 
indeed we found that over 60% of sarcomas were characterized by a strong and 
widespread Twist1 nuclear accumulation, often associated with TWIST1 gene copy-
number gain. 
The remarkable inverse correlation between Twist1 expression and TP53 gene 
mutations in leiomyosarcomas and between Twist1 and MDM2 accumulation 
observed in liposarcomas hinted that Twist1 may act as an alternative mechanism 
to hamper p53 response in these tumors. This hypothesis was corroborated by the 
finding that Twist1 actually replaces either shp53 or MDM2 in an in vitro 
transformation models of human fibroblasts and indicated that Twist1 may 
complement the transformation of human mesenchymal cells by antagonizing p53. 
These conclusions were corroborated by the observation that the manipulation of 
Twist1 expression in sarcoma cells affects p53 stability and response. 
Twist was originally described by our group to inhibit the expression of ARF 
(Maestro et al., 1999) and this mechanism is likely to contribute to Twist oncogenic 
properties. Nevertheless, here we report that Twist1 is capable of promoting MDM2-
mediated degradation of p53 and attenuation of p53-mediated transcription and 
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response (apoptosis, premature senescence, cell cycle progression) even in 
INK4a/ARF-defective cell contexts, which indicates that Twist1 affects p53 also 
through an ARF-independent route. Most evidence linking Twist to cancer refer to 
the ability of Twist proteins to modulate the expression of target genes (including E-
cadherin, Bmi1, YB1, CD24, AKT2, FGFR2, PDGFRα) by binding E-box consensus 
sites on their promoters (Cakouros et al., 2010; Casas et al., 2011; Cheng et al., 
2007; Eckert et al., 2011; Lee et al., 2009; Shiota et al., 2008b; Sokol and Ambros, 
2005; Vesuna et al., 2008; Yang et al., 2004; Yang et al., 2010). We had provided 
evidence that Twist1 interferes with p53 functions through an E-box independent 
mechanism. In fact, Twist1 mutants defective in DNA binding retained the ability to 
interfere with p53-induced transcription and apoptosis. Thus, the data collected by 
our laboratory indicated that Twist1 promotes the bypass of p53 tumor suppressor 
pathway apparently through molecular mechanisms different from those that 
facilitate EMT and metastatic progression of carcinomas. 
We eventually hypothesized that Twist1 inhibited p53 by direct targeting. Indeed, in 
vitro and in vivo experiments corroborated the notion that Twist directly interacts 
with p53 and it does so through the domain named Twist box. This sequence 
corresponds to a 20-Aa stretch at the C-terminus of the protein which is identical 
both in Twist1 and Twist2. Literature data indicate that the Twist box mediates the 
direct interaction between the Twist proteins and RunX2, thus preventing RunX2 
from activating the osteogenic program (Bialek et al., 2004). The same region is 
involved also in the inhibitory binding to MEF2 (Spicer et al., 1996), ATF4 (Danciu et 
al., 2012) and RelA (Sosic et al., 2003), suggesting that Twist box-mediated binding 
is a common theme in the inhibition exerted by Twist on other transcription factors. 
Here we demonstrate that both Twist protein may establish direct interaction with 
the CTD regulatory domain of p53 and provide a mechanistic explanation as how 
this interaction may affect p53 activity. In fact, docking simulations indicate that the 
interaction between the Twist box and p53 CTD involves Ser392, one of the most 
conserved p53 residues. Several kinases have been reported to be able to target 
Ser392 in vitro, but it is still unclear which enzyme physiologically catalyzes Ser392 
phosphorylation in vivo (Xu, 2003). Furthermore, despite the numerous evidence of 
the importance of Ser392 in modulating the p53 response, the actual mechanism by 
which this modification affects p53 function is largely unknown. Phosphorylation of 
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p53 at Ser392 (Ser389 in mouse) has been reported to take place following different 
stresses, including UV -but not gamma- radiation, oncogene activation, growth 
factor deprivation and oxidative damage. This modification is known to stabilize 
tetramer formation and activate p53 site-specific DNA binding (Hupp et al., 1992; 
Kapoor et al., 2000; Nichols and Matthews, 2002; Sakaguchi et al., 1997; Yap et al., 
2004). Moreover, mouse models expressing a p53 allele impaired for Ser392 
phosphorylation (S389A corresponding to S392A in human) display increased 
sensitivity to DNA damage induced carcinogenesis. This fact supports the critical 
role of this phosphorylation site in p53 tumor suppressive functions (Bruins et al., 
2004; Cox and Meek, 2010; Hoogervorst et al., 2005; Jackson et al., 2004; Yap et 
al., 2004).  
Here we show that Twist1 not only prevents CK2-mediated phosphorylation of p53 
at Ser392 in an in vitro assay, but also that modulation of Twist expression in 
sarcoma cell lines significantly affects the extent of phosphorylation of p53 at this 
site in vivo, which correlates with reduced p53 stability and activity.  
How does these information fit with the current knowledge about p53? The 
canonical domain of p53 involved in the interaction with MDM2 is the first 
transactivation domain (TAD-I) located at the very N-terminus of the protein (Kussie 
et al., 1996; Lin et al., 1994). Following genotoxic and non-genotoxic stresses this 
region undergoes post-translational modifications that weaken the affinity of p53 for 
MDM2, thus allowing p53 stabilization (Jones et al., 2005; Prives, 1998). Very 
recently, Prive’s group has demonstrated that also the C-terminus of p53 
contributes to the binding to MDM2 and that the p53:MDM2 interaction is hampered 
by C-terminal modifications of p53 (Poyurovsky et al., 2010). The authors 
addressed in particular the effect of p53 CTD acetylation on MDM2:p53 complex 
formation, but the same authors suggest that other post-translational modifications 
at the CTD are likely to impinge on this interaction. In agreement with this 
hypothesis, we show that a Ser392 phospho-mimic mutant displays a reduced 
affinity to MDM2 compared to a Ser392 non-phosphorylable allele. Thus, it is 
possible that the post-translational modification of Ser392 as such may specifically 
affect the binding between MDM2 and C-terminus p53. In this scenario Twist1, by 
hindering Ser392 phosphorylation, might facilitate MDM2:p53 CTD complex 
formation and then p53 degradation. Instead, we suggest another possible 
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explanation of Twist1-promoted degradation of p53. In fact, Lozano and coworkers 
have recently proposed that an interplay may exist between Ser392 and Ser15 
(Kapoor et al., 2000). Ser15 is known to inhibit MDM2 from binding to p53 and 
dictate other N-terminal phosphorylations that regulate p53 stabilization (Saito et al., 
2003; Shieh et al., 1997). By using phospho-mimic mutants, we show that the 
phosphorylation status at Ser392 dictates the extent of phosphorylation at Ser15, 
but not vice versa. Therefore, by acting on Ser392, Twist1 in turns affects also the 
extent of Ser15 phosphorylation, thus facilitating the canonical route of MDM2-
mediated degradation of p53.  
Finally, in agreement with recent observations (Lee and Bar-Sagi, 2010; Kogan-
Sakin et al., 2011), we found that Twist1 was transcriptionally induced in response 
to oncogene activation in human primary fibroblasts. This data suggests a scenario 
where oncogenic transformation results in the induction of Twist1. In turn, Twist1 
promotes the bypass of oncogene-induced p53 safeguard programs by both 
inhibiting the ARF/p53 signalling and by preventing key phosphorylation through 
direct interaction, thus facilitating MDM2-mediated degradation. 
In conclusion, by addressing the role of Twist1 in the context of sarcomas, our study 
unveils an unprecedented mechanism of p53 inactivation. The model here 
proposed, which is likely to apply also to other tumor types displaying aberrant 
expression of Twist proteins, provides the proof of principle that targeting Twist1-
p53 complex may offer additional avenues for the treatment of p53 wild type 
cancers (Piccinin et al., 2012). 
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EXPERIMENTAL PROCEDURES 
 
Immunohistochemistry and FISH 
Primary sarcoma samples were retrieved from the tissue banks of the Treviso 
General Hospital and the San Raffaele Scientific Institute in Milan, where they were 
analyzed with patients’ consent. None of the patients had received radio- or chemo-
therapy prior surgery. Tumor specimens were obtained in accordance with the 
Institutional Review Boards and de-identified before analysis, thus qualifying for 
exemption from human subjects statements. 
Immunohistochemistry was performed on 5-μm sections using an automatic 
immunostainer (Bond System, Leica Microsystems). A non-biotin detection system 
(Bond Polymer Refine, Leica Microsystems) and diaminobenzidine development 
were employed. Heat-induced antigen retrieval was performed using Tris-EDTA 
buffer (pH 9.0) in a water bath at 95°C for 30 min. 
The antibodies used were: Twist1 (Twist2C1a, Santa Cruz), Twist 2 (ab6603, 
Abcam), p53 (DO-7, Labvision), MDM2 (1F2, Oncogene Science). Twist1 and 
Twist2 antibodies were first validated for specificity by immunohistochemistry on 
mouse embryo sections, and by immunoblot on recombinant GST-hTwist1, GST-
hTwist2 and on cells ectopically expressing hTwist1 and hTwist2. No cross 
reactivity was observed. 
Fluorescence In Situ Hybridization (FISH) was carried out according to standard 
protocols on samples for which frozen material was available (Cangi et al., 2008). 
The BAC clone RP11-960P19 (Invitrogen) mapping on chromosome 7p21 
(chr7:19,058,477-19,247,823) was labeled with SpectrumOrange by Nick 
Translation labeling Kit (Abbott Molecular). Chromosome localization (7p21) was 
confirmed on metaphase spreads from normal peripheral lymphocytes. The 
inclusion of the TWIST1 locus in the clone was confirmed by PCR-direct 
sequencing. A centromere 7 probe (Aquarius, Cytocell) was used for normalization. 
FISH was performed on frozen sections utilizing Nikon Eclipse 90i microscope and 
Genikon Software (Nikon). One hundred interphase nuclei were analyzed for 
experiment. 
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p53 mutation analysis 
Mutation analysis of TP53 was performed by PCR direct-sequencing on genomic 
DNA extracted from paraffin-embedded tissue sections as previously described (Dei 
Tos et al., 1997) 
 
Cell culture, transfections and retroviral infections 
E1A/Ras transformed mouse embryo fibroblasts (ER-MEF and ER-p53-/- MEF) 
were kindly provided by S. W. Lowe (MSK Cancer Center, New York), p53-/- MEF 
and p53-/- MDM2-/- double null MEF by G. Lozano (MD Anderson, Huston), 
HCT116 and p53-/- HCT116 by B. Vogelstein (Sidney Kimmel Cancer Center, 
Baltimore), U2-OS myc-ER by M. Eilers (University of Wurzburg); the Ewing’s 
sarcoma cell lines Sal-1 and WE-68 were a kind gift from G. Hamilton (University of 
Vienna) and F. Van Valen (University of Munster), respectively. HT-1080 
(fibrosarcoma), SK-UT-1 (leiomyosarcoma), SAOS-2 and U2-OS (osteosarcoma), 
MES-SA (undifferentiated Mullerian uterine sarcoma), SJSA (Bone sarcoma), BJ 
(human primary fibroblasts) were from American Type Culture Collection (ATCC). 
VA-ES-BJ (epithelioid sarcoma) were from ICLC Interlab Cell line Collection 
(Genova). The human breast carcinomas MCF-7 cells, used as a negative control 
for Twist1 expression, were from ATCC. 
All cell lines listed above were maintained in a humidified incubator with 5% CO2 
and propagated in DMEM supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), with the exception of Sal-1, WE-68 and SJSA which were grown in 
RPMI plus 10% FBS. 
BJ and h-Tert-immortalized BJ were grown in Advanced-MEM plus 10% FBS and 
non-essential aminoacids. 
Transfections, retroviral infections and reporter assays using the PG13-Luc plasmid 
(which carries the firefly luciferase gene under the control of 13 p53-responsive 
elements) were as previously described (Demontis et al., 2006; Maestro et al., 
1999). 
 
Plasmids 
pCS2 6xmyc-Twist1 full length, Δb and R114P mutants, containing 6Xmyc-tag at 
the N-terminus of mouse Twist1 cDNA, were a kind gift of A. Lassar (Spicer et al., 
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1996). All the other pCS2 myc-tag Twist mutants were obtained by site-directed 
mutagenesis (QuikChangeTM Site Directed Mutagenesis Kit, Stratagene) and 
checked by sequencing. pBabe myc-Twist constructs were obtained by subcloning 
myc-Twist wild-type and mutant cDNAs from pCS2 as BamHI/SnaBI fragments into 
pBabe Puro (BamHI/SnaBI). pLPC and MarxIVHygro myc-Twist constructs were 
obtained by subcloning myc-Twist from pBabe (as BamHI/EcoRI fragment) into 
pLPC and MarxIVHygro (BamHI/EcoRI). Twist2 was cloned into pCDNA3 and 
pLPC. Twist proteins were obtained by subcloning Twist cDNAs into pGEX-KG 
vector (GE Healthcare Life Science). Human Twist1 cDNA was kindly supplied by F. 
Perrin-Schmitt (Institut National de la Santé et de la Recherche Médicale, 
Strasbourg, France) and subcloned into pCDNA3. pWZL neo E1A, pWZL Hygro 
HRasVal12, pLPC MDM2, pLPC dnp53 (H175), pRetroSuper shp53, pLPC eGFP, 
pBABE Zeo h-Tert were previously described (Di Micco et al., 2006; Seger et al., 
2002). pCDNA3 p53 mutants (299X, 256-393 and 294-393), pRSETB-Hisp53 were 
a generous gift of G. Del Sal (University of Trieste, Italy). p53 mutants at Ser392 
(S392A and S392E) were generated by site-directed mutagenesis from pCDNA3 
hp53 and pLPC hp53 encoding wild type p53. pDNA3 p53 wild type, S392A, S392E 
and pCS3-myc eGFP were used to assess the effect of myc-tag Twist1 on ectopic 
p53 levels. PG13-luc p53-responsive reporter was kindly provided by B. Vogelstein 
(Sidney Kimmel Comprehensive Cancer Center, Baltimore). Acute silencing of 
Twist1 was performed by transfecting a mix of four either human or mouse Twist1-
specific siRNAs (ON-TARGETplus SMART pool Dharmacon), using a Non-targeting 
Pool as a control, according to the manufacturer’s instructions. Stable silencing of 
Twist1 was achieved by retroviral infection of a validated Twist1-specific shRNA 
(shTwist1A and shTwist1B) cloned in pRetroSuper (Ansieau et al., 2008; Yang et 
al., 2004). Data were confirmed with both constructs. pRetroSuper-shGFP and 
shLuc were used as negative controls. 
 
Antibodies and protein expression analyses 
Protein cell lysates were generated using RIPA buffer in the presence of protease 
and phosphatase inhibitors (Santa Cruz). Tumor protein extraction was performed 
using a Qiagen Tissuer Lyser (Qiagen). Protein lysates were separated by SDS-
PAGE and transferred onto nitrocellulose membrane (Protran, Whatman). The 
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antibodies used in this study were: mouse monoclonal anti-p53 (DO1, Santa Cruz), 
rabbit polyclonal anti-p53 (CM5, Calbiochem) anti-Twist1 (Twist2C1a, Santa Cruz), 
anti-myc (9E10, Oncogene Science), anti-polyHistidine (Clone HIS-1, Sigma), anti-
E1A (M58 and M73, Abcam), anti-H-Ras (OP-23, Oncogene Science), anti-MDM2 
(2A10, Oncogene Science), rabbit polyclonal anti-Bax (#2772, Cell signaling), anti-
Puma (#4976, Cell signaling), anti-p21 (#70, BD Transduction Laboratories ), anti-
FLAG (F3165, Sigma), rabbit polyclonal anti-phospho Ser392 p53 (ab3257 and 
ab59207, Abcam), rabbit polyclonal anti-phospho Ser15 p53 (#9284, Cell signaling), 
anti-GST (#2622, Cell signaling), rabbit polyclonal anti-acetyl-p53 (Lys379, #2570 
Cell signaling), rabbit polyclonal anti-acetyl-p53 (Lys373, #06-916 Millipore). Mouse 
monoclonal anti-γ-tubulin (Clone GTU-88, Sigma) or anti-GAPDH (MAB374, 
Chemicon International) were used for normalization. For immunohistochemistry the 
antibodies used were: Twist1 (Twist2C1a, Santa Cruz), Twist 2 (ab6603, Abcam), 
p53 (DO-7, Labvision) and MDM2 (1F2, Oncogene Science). Expression analyses 
were performed with either the Odyssey Infrared (Li-Cor Biosciences) or the 
Chemidoc (BioRad) Imaging system. Integrated intensities of the bands were 
measured using the dedicated application software. 
          Co-immunoprecipitation assays were performed on both naive and 
transfected cells, 48 hours post-transfection. Three million cells were lysed in 1 ml 
Protein Lysis Buffer (PLB: 20mM Tris-Cl pH 8.0, 150mM NaCl, 5mM MgCl2, 0.2 mM 
EDTA and 0.1% Nonidet-P40) supplemented with protease inhibitors and 1mM 
PMSF, pre-cleared with 100 μl of 50% slurry protein G-Sepharose 4 Fast Flow (GE 
Healthcare Bio-Sciences AB) and then incubated for 3 hours at 4°C with 1 μg of the 
appropriate MoAb previously conjugated with Protein G-Sepharose. After 
incubation, beads were washed, resuspended in 20 μl of 2XLaemmli buffer and 
boiled. Proteins were separated by SDS-PAGE and analyzed by Western blotting 
with the indicated antibodies.  
Immunoprecipitation of MDM2 and p53 complexes was performed in the presence 
of the proteasome inhibitor MG132 (10 μM, 8hr) (Sigma Aldrich). 
          Direct interaction between recombinant proteins was determined by 
combining 5 μg of His-p53 bound to the Ni-NTA agarose resin (Qiagen) together 
with 15 μg of either GST-Twist or GST-only recombinant protein in PLB for 2 hours 
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at 4°C. After incubation, beads were extensively washed, then resolved by SDS-
PAGE. 
          For GST pull-down experiments, indicated proteins were in vitro translated 
(IVT) with [35S]-methionine (Perkin Elmer) using the TNT System (Promega). IVT-
proteins were incubated together with 5 μg of the indicated bacterially expressed 
GST-fusion protein in PLB plus 30 μl of 50% slurry Glutathione Sepharose Resin 
(GE Healthcare). The resin was incubated for 2 hours at 4°C, then extensively 
washed. Bound proteins were separated by SDS-PAGE. Gels were stained with 
Coomassie Brilliant Blue, dried and exposed to X-ray films (Kodak). For detecting 
the binding between N-terminus Twist1 and p53 milder binding conditions were 
used (20mM Tris-Cl pH 8.0, 100mM NaCl, 5mM MgCl2, 0.2 mM EDTA and 0.02% 
Nonidet-P40). 
          For cycloheximide (CHX) chase experiments, cells were treated with CHX 
(100 μg/ml for HT-1080, VA-ES-BJ, p53-/- HCT116; 250 μg/ml for SAOS-2), 
harvested at time 0, 15min, 30min, 1hr, 2hr, 4hr, 6hr, lysed and analyzed by SDS-
PAGE. 
 
SA-ß-gal staining 
For the detection of premature senescence by SA-β-gal staining , the cells were 
seeded at 50% confluence in a 6 cm plate, washed in PBS and then fixed for 5 min 
at room temperature with a 0.05% glutaraldehyde solution. Later, cells were washed 
with PBS supplemented with 1mM MgCl2 and stained in acidic X-gal solution 
(1mg/ml X-gal, 0.12 mM K Fe3 [CN]6, 0.12mM K4[CN]6, 1mM MgCl2, pH 6) at 
37°C for 5-10 hr. 
 
Cell counting and apoptosis  
A well established model of oncogene-induced p53-mediated apoptosis (E1A/Ras 
MEF, ER-MEF) (Lowe and Ruley, 1993; Lowe et al., 1993) was used for apoptotic 
assays. Serum starvation and mild genotoxic stress (0.1 μg/ml Doxorubicin) were 
used to trigger apoptosis, as previously described (Demontis et al., 2006; Maestro 
et al., 1999). Cell viability was assessed by Trypan blue assay. Survival rates were 
confirmed with the Viacount assay read on a Guava PCA Instrument. Experiments 
were done in triplicates on at least two different retroviral infections. Histograms 
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indicate the mean percentage of cells that survived the apoptotic stress (100X 
treated viable cells/untreated viable cells), plus SD.  
 
In vivo tumorigenicity assay 
Experiments on animals were performed in accordance with national regulations 
and were approved by the CRO ethical committee for animal experimentations. All 
experiments conform to the relevant regulatory standards. 
hTert-immortalized (pBabeZeo-hTERT) BJ human primary fibroblasts were co-
infected with pWZLhygro- HRASV12 and pWZLneo-E1A. After drug selection, cells 
were further infected with a pLPC vector encoding either MDM2, dnp53 (H175), 
shp53 or Twist constructs. pLPC empty vector was used as a control. After 
puromycin selection, 5 x106 cells were subcutaneously injected into each flank of 
six-week-old athymic nude mice (Hsd: Athymic nude-nu, Harlan) as previously 
described (Seger et al., 2002). For pRetroSuper-shLuc and pRetroSuper-shTwist 
HT-1080, 1 x106 cells were used. Tumor size was monitored weekly. Mice were 
sacrificed at week 5. Tumor volume was calculated as 2r3. 
 
Protein modeling and docking simulations 
Three dimensional model structure of both Twist1 and p53 were built using the web 
server SAM-T08 (Karplus et al., 2009) and further minimized by simulated 
annealing using the program CNS (Brunger et al., 1998). Docking calculations were 
carried out by the web server ClusPro2.0 (Comeau et al., 2007) through a 
systematic, rigid-body search of the first molecule translated and rotated about the 
second. The intermolecular energies for all configurations generated by this search 
were calculated as the sum of electrostatic and Van der Waals energies. After 
choosing the lowest energy solutions, these were clustered together and the lowest 
energy individual from the most populated cluster was considered as a successful 
candidate. In our case, clusterization was particularly favorable being the lowest-
energy cluster populated by 187 individual while the second lower by 85. We also 
checked the likelihood of an interaction between Twist1 and the DNA-binding “core” 
region of p53. To this end, to perform the docking calculation, as a receptor, we 
used the crystallographic structure of p53 “core domain” (Cho et al., 1994) [PDB 
code 1TUP]. After editing the coordinate file to delete water and DNA molecules, we 
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run ClusPro2.0 using the same parameterization as previously described. In this 
case, the lowest energy cluster was populated by 55 individual being the second 
and the third lower populated by 54 and 50 individual respectively, thus indicating 
an unfavorable conformation for p53 region chosen. 
 
In vitro CK2 assay 
Purified His-p53 was pre-incubated with either GST-Twist box or GST only (0.25, 
0.5, 1g) for 1 hr at 4°C in 40l of Kinase buffer (Biolabs) to allow protein 
interaction. After pre-incubation, kinase reaction was performed for 1 hr at 30°C in 
the presence of 0.025U of purified CK2 (Biolabs) and terminated by addition of 
sample buffer. Protein were then separated by SDS-PAGE and analyzed by 
western blot using anti-phosphoSer392, anti-p53 and anti-GST antibodies. 
 
Real-time PCR (RT-PCR) 
The mRNAs of hTert-immortalized (pBabeZeo-hTERT) BJ human primary 
fibroblasts co-infected with pWZLhygro- HRASV12 and pWZLneo-E1A, alone or in 
combination, were extracted with Bio-Robot EZ1 (Qiagen) and the cDNAs were 
prepared with Superscript III (Life Technologies, Ltd) according to the 
manufacturer’s instructions. The cDNAs were amplified by PCR in an CFX96 RT-
PCR detection system (BioRad) with the fluorescent double-stranded DNA-binding 
dye EVA Green (BioRad). Specific primers for each gene were designed to work 
under the same cycling conditions (95°C for 10min followed by 40 cycles at 95°C for 
30s and 55°C for 1min), generating products of comparable sizes. For each 
reaction, standard curves for references genes were constructed based on six 4-
fold serial dilutions of cDNA. All samples were run in triplicate. The relative amount 
of gene expression was normalized on the average of expression levels of 3 
different housekeeping genes (CFL1, GAPDH and -actin). 
   
 
Statistical analysis 
Data shown are means ± SD (standard deviation) of at least three independent 
experiments. Comparisons of proportions were performed with a two-tailed Fisher’s 
exact test. 
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SUMMARY
Twist proteins have been shown to contribute to cancer development and progression by impinging on
different regulatory pathways, but their mechanism of action is poorly defined. By investigating the role of
Twist in sarcomas, we found that Twist1 acts as a mechanism alternative to TP53mutation and MDM2 over-
expression to inactivate p53 in mesenchymal tumors. We provide evidence that Twist1 binds p53 C terminus
through the Twist box. This interaction hinders key posttranslational modifications of p53 and facilitates
its MDM2-mediated degradation. Our study suggests the existence of a Twist box code of p53 inactivation
and provides the proof of principle that targeting the Twist box:p53 interactionmight offer additional avenues
for cancer treatment.
INTRODUCTION
Twist1 and Twist2 (collectively hereafter referred as ‘‘Twist’’) are
closely relatedmembers of a family of bHLH transcription factors
involved in gastrulation and mesoderm specification. Typically,
Twist proteins regulate the expression of target genes by
binding, as homo- or heterodimers, to E-box-containing pro-
moters. Consistent with the role in tissue specification, the
expression of Twist1 in mouse embryo follows mesoderm
induction and becomes negligible in adult mesenchymal
tissues, except a population of quiescent mesodermal stem
cells. Twist2 is also involved in mesoderm development, but its
activation occurs later than Twist1 and is essentially restricted
to the dermis (Barnes and Firulli, 2009; Castanon and Baylies,
2002; Qin et al., 2012; Tukel et al., 2010).
Twist proteins were first associated with cancer on the basis
of their ability to promote the bypass of cellular safeguard
programs. Both genes were isolated through a genetic screen
for cDNAs capable of overriding Myc-induced apoptosis, and
Twist1 was found to be overexpressed in rhabdomyosarcomas,
where it was suggested to support oncogenic transformation
and to inhibit myogenic differentiation (Maestro et al., 1999).
Subsequently, de novo Twist1 activation was reported in several
types of cancer including neuroblastomas (Valsesia-Wittmann
et al., 2004) and carcinomas, where it was shown to contribute
to metastatic progression through the induction of epithelial-
mesenchymal transition (EMT) (Karreth and Tuveson, 2004;
Yang et al., 2004). A role for Twist proteins in stemness has
also recently emerged (Cakouros et al., 2010; Vesuna et al.,
2009).
Significance
Although sarcomas are relatively rare tumors, their aggressive behavior, resistance to therapies, and often early-age onset
make them one of the most challenging types of cancer. Intriguingly, despite clear evidence of attenuation of the p53
response, a large fraction of sarcomas retain wild-type TP53, indicating that mechanisms different frommutations account
for p53 inactivation in these tumors. Here, we provide evidence that Twist1-induced destabilization of p53 represents an
important strategy of attenuation of the p53 response in sarcomas. We show that Twist1 accumulates mostly in tumors
that retain wild-type TP53. Moreover, we show that, by establishing direct interaction, Twist1 hinders key phosphorylations
of p53 and facilitates its degradation. Thus, targeting the Twist1:p53 interaction might offer additional avenues for cancer
treatment.
404 Cancer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier Inc.
The different consequences of constitutive Twist expression
suggest that these transcription factorsmay contribute to tumor-
igenesis and neoplastic progression through different routes. In
particular, Twist1 has been demonstrated to bind the E-cadherin
promoter to suppress its transcription, thus facilitating EMT and
metastatic spreading of epithelial tumors (Karreth and Tuveson,
2004; Yang et al., 2004). Twist proteins have also been shown to
suppress the transcription of p19ARF, thus attenuating onco-
gene-induced p53 response, and p16INK4a, thus allowing
cancer cells to escape Rb-mediated cell cycle control (Ansieau
et al., 2008; Feng et al., 2009; Kwok et al., 2007; Lee and
Bar-Sagi, 2010; Li et al., 2009; Maestro et al., 1999; Shiota
et al., 2008; Stasinopoulos et al., 2005; Valsesia-Wittmann
et al., 2004; Vichalkovski et al., 2010). Moreover, Twist mediates
mesenchymal stem cell self-renewal, and Twist1-induced EMT
requires BMI1, thus linking EMT and stemness (Isenmann
et al., 2009; Yang et al., 2010). Finally, it has been proposed
that EMT and bypass of safeguard programs might represent
two sides of the same coin (Ansieau et al., 2008). Overall, the
emerging picture is that Twist proteins play important roles in
cancer, but the fact that they intersect multiple different path-
ways makes it hard to dissect the mechanisms of action as
EMT/metastasis factors and as primary oncogenic drivers.
Sarcomas represent a heterogeneous group of mesenchymal
tumors that account for about 5% of adult and 10% of pediatric
neoplasias. Sarcomas include over 60 histopathological cate-
gories and are broadly classified into two cytogenetic groups,
complex and simple karyotype, and these latter are often char-
acterized by reciprocal translocations or targeted amplifications
(Borden et al., 2003; Fletcher et al., 2002; Helman and Meltzer,
2003). A large fraction of localized sarcomas, especially the
simple karyotype ones, retain wild-type TP53 but their p53
response is attenuated. Thus, other, still elusive, mechanisms
are likely responsible for p53 inactivation in these tumors.
We reasoned that, being mesenchymal in nature, sarcomas
offer the opportunity to discern the functions of Twist related to
the induction of EMT, typically occurring in carcinomas, from
those more specifically related to the interference with tumor-
suppressive pathways. Thus, in the attempt to provide a better
understanding on how Twist contribute to tumorigenesis, we
sought to investigate the role of Twist in antagonizing p53,
focusing on sarcomas as a tumor model.
RESULTS
Twist1 Is Overexpressed and Undergoes Copy-Number
Gain in Sarcomas
To assess the oncogenic role of Twist in the context of mesen-
chymal tumors, 146 sarcomas and adjacent normal tissues
were investigated by immunohistochemistry (IHC). With the
exception of dermal fibroblasts, where scattered nuclear reac-
tivity was observed, normal adult mesenchymal tissues were
essentially negative for Twist1. In contrast, a strong and diffuse
nuclear accumulation of Twist1 was observed in over 60% of
soft-tissue sarcomas of different subtypes (Figure 1A; see
Table S1 available online). Overexpression of Twist2 was
uncommon in sarcomas (6/84 cases) and sarcoma cell lines
(Figure S1A). Fluorescence in situ hybridization (FISH) analyses
with a probe encompassing the TWIST1 locus revealed that, in
9 of 19 (47%) Twist1 IHC+ frozen samples, Twist1 accumulation
was associated with TWIST1 copy-number gain (Figure 1B;
Table S2).
In light of the role of Twist1 in EMT, we then compared Twist1
expression pattern in sarcomas and carcinomas. In contrast to
the widespread and robust accumulation detected in sarcomas,
a weak-moderate nuclear expression of Twist1 was observed in
10%–30% of breast, colorectal, prostate, and lung carcinomas,
often confined to the invasion front (Figure 1A; Table S3).
Twist1 Overexpression Serves as an Alternative
Mechanism of p53 Inactivation during Sarcomagenesis
Because mutations of TP53 are rare in sarcomas and Twist1 has
been suggested to attenuate the p53 pathway (Ansieau et al.,
2008; Feng et al., 2009; Kwok et al., 2007; Lee and Bar-Sagi,
2010; Li et al., 2009; Maestro et al., 1999; Shiota et al., 2008;
Stasinopoulos et al., 2005; Valsesia-Wittmann et al., 2004;
Vichalkovski et al., 2010), we asked whether the overexpression
of Twist1 could account for p53 inactivation in sarcomas retain-
ing wild-type TP53. We first focused on leiomyosarcomas (LMS),
a sarcoma subtype that has one of the highest frequencies of
TP53 mutations (Dei Tos et al., 1996; Hall et al., 1997). In partic-
ular, we analyzed localized/nonmetastatic tumors because
sarcomas may acquire p53 mutations that contribute to tumor
aggressiveness during progression (Cordon-Cardo et al.,
1994). Among the 35 LMS analyzed, overexpression (>25%
positive cells) of p53, Twist1, Twist2, and MDM2 were found in
14, 15, three, and four cases, respectively (Table S4). TP53
missense mutations were found in eight cases (Figure 1C), all
displaying strong nuclear accumulation of p53; no mutation
was detected in samples that were negative or with focal/patchy
p53 immunostaining. Fourteen of 15 Twist1+ cases retained
wild-type TP53, the only exception being a case that was also
positive for MDM2. Thus, although not reaching the conventional
5% level of statistical significance, probably in part because of
the small sample size of these clinically rare tumors, the clus-
tering of Twist1-positivity among p53 wild-type LMS suggests
that overexpression of Twist1 may serve as a mechanism
alternative to TP53 mutations to inactivate the p53 response in
these tumors. To corroborate the role of Twist1 in inhibiting
p53, we then focused on liposarcomas (LS), which include
well-differentiated (WD) and dedifferentiated (DD) LS, and
myxoid/round cell (myxoid) LS. These LS display a simple karyo-
type and often retain the wild-type TP53. WD and the more
aggressive DD LS, which are considered the same entity at
different malignant stages, typically carry the amplification of
the chromosome region harboring the MDM2 locus (Fletcher
et al., 2002), and their p53 is inactivated as a result of enhanced
MDM2-mediated degradation. In contrast, the mechanism of
inactivation of p53 in myxoid LS, which are negative for
MDM2, remains unclear (Coindre et al., 2010; Mentzel and
Fletcher, 1995). In a series of 24 LS, all molecularly confirmed
to be TP53 wild-type, we observed an inverse correlation
between Twist1 andMDM2 overexpression: Twist1 was robustly
overexpressed in 13 of 14 MDM2 myxoid LS, whereas only
2 of 10 MDM2+ WD and DD LS expressed Twist1 (p = 0.00049)
(Figures 1A and 1C). Thus, Twist1 and MDM2 appear to be
essentially mutually exclusive in LS, supporting the notion that
Twist1 may inactivate p53 in mesenchymal tumors.
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To functionally validate the role of Twist1 as an antagonist of
p53 during sarcomagenesis, we then probed its ability to
complement the transformation of human primary fibroblasts.
We showed previously that BJ human fibroblasts upon ex-
pression of HRasV12 and E1A (RE-BJ) gain a transformed
phenotype in culture but display negligible tumorigenic acti-
vity in xenograft assays. RE-BJ cells become tumorigenic
following inactivation of the p53 pathway (Di Micco et al.,
2006; Seger et al., 2002). We found that Twist-transduced
RE-BJ also generated tumors when injected into immunocom-
promised mice, supporting that Twist proteins may actually
sustain oncogene-induced transformation of cells of mesen-
chymal origin at least in part by antagonizing p53 (Figures
1D, S1C, and S1D).
Figure 1. Twist1 Is Overexpressed in Human Sarcomas and Supports the Oncogenic Transformation of Primary Mesenchymal Cells
(A) Immunostaining for Twist1 in sarcomas and in carcinomas. Scale bar: 100 mm.
(B) FISH analysis of TWIST1 in sarcomas overexpressing Twist1. TWIST1 probe (RP11-960P19) is in red; chromosome 7 centromeric probe (Alpha-Satellite 7) in
green. An example of copy-number gain involving the whole chromosome 7 (left panel) and of selective amplification of the TWIST1 locus (right panel) are shown.
Scale bar: 10 mm.
(C) Expression of Twist1 in LMS according to TP53 mutation status (upper) and in LS according to MDM2 expression (lower). The p value was calculated
according to the Fisher’s exact test.
(D) Twist1 and Twist2 induce tumorigenic conversion of RE-BJ cells. The table indicates the number of tumors generated by each oncogenic combination in a set
of injections. MDM2, a dominant-negative TP53 allele (dnp53, R175H), and a shRNA targeting p53 (shp53) were used as positive controls. Representative images
of RE-vector and RE-Twist1 xenografts are shown in the middle panel. Tumor size was measured weekly. The right panel shows the kinetics (average volume of
tumors, ± SD) of representative tumors.
See also Figure S1 and Tables S1, S2, S3, and S4.
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Twist1 Enhances MDM2-Mediated Degradation of p53
We then assessed the effect of modulation of Twist expression in
a series of human sarcoma cell lines expressing wild-type p53
(Figures S1A and S1B). Downregulation of the endogenous
Twist1 by either stable expression of Twist1-specific shRNAs
(Ansieau et al., 2008; Yang et al., 2004) or transient transfection
of siRNAs stabilized p53 (Figure 2A). Conversely, ectopic Twist1
expression in Twist1 sarcoma cells reduced the p53 protein
level, without affecting p53 transcription (data not shown). This
downregulation was reversed by proteasome inhibition, sug-
gesting that Twist1 promotes p53 proteasomal degradation
(Figure 2B). Accordingly, cycloheximide (CHX)-chase assays
indicated that the p53 half-life was increased from 1 hr to
3 hr in Twist1-silenced HT-1080 cells, whereas it was reduced
from45min to20min in VA-ES-BJ expressing ectopic Twist1
(Figure 2C). Moreover, cotransfection of Twist1 together with
p53 resulted in a slight but consistent reduction in p53 levels
(30%) in MDM2-proficient (p53/) but not in MDM2-deficient
Figure 2. Modulation of Twist1 Expression Affects p53 Response and Tumorigenicity in Sarcoma Cells
(A) Immunoblot of cells silenced for endogenous Twist1 expression by either shRNA (left) or siRNA (right). As a control (Ctr), shLuc and nontargeting siRNA pool
were used, respectively. Protein levels were normalized to GAPDH.
(B) Immunoblot of cells ectopically expressing either Twist1 (Tw) or GFP, as a control (Ctr). Cells were exposed to MG132 (10 mM) or vehicle (DMSO) for 4 hr, then
harvested.
(C) Cycloheximide-chase assays (CHX, 100 mg/ml) in Twist1-silenced HT-1080 and in VA-ES-BJ engineered to express ectopic Twist1. shGFP (shCtr) and GFP
(Ctr) were used as controls, respectively.
(D) Immunoblot of p53/ and p53/;Mdm2/MEF cotransfected with ectopic p53 (5 mg) and either myc-Twist1 (Tw) or empty control vector (Ctr) (15 mg). GFP
(1 mg) was used as a control of transfection. p53 expression levels (ect. p53) were corrected for transfection efficiency (p53/GFP ratio). This result was confirmed
on three independent experiments.
(E) BrdU incorporation assay in Twist1-silenced HT-1080 and Sal-1 cells. Histograms represent the mean plus SD.
(F) Xenograft growth of Twist1-silenced HT-1080 cells. Curves represent the average tumor volumes ± SD.
(G and H) HT-1080 cells were engineered to express combination of two shRNAs in pRS-Hyg and -Neo, as indicated. Controls (Ctr) were shGFP and shLuc. Cells
were seeded overnight and then were shifted to serum-free medium. Cell viability (G) and caspase 3/7 activation (H) were assessed 48 hr after starvation.
Histograms represent mean values plus SD.
(I) HT-1080 cells engineered and serum starved as in (G) and (H) were immunoblotted for the indicated proteins.
See also Figure S2.
Cancer Cell
A Twist box Code of p53 Inactivation
Cancer Cell 22, 404–415, September 11, 2012 ª2012 Elsevier Inc. 407
(p53/; Mdm2/) mouse embryo fibroblasts (MEF) null for
endogenous p53 (Figure 2D), supporting a role for MDM2 in
Twist1-induced downregulation of p53.
Silencing of Twist1 Activates a p53 Response
in Sarcoma Cells
Under standard culture conditions, Twist1-depleted cells ex-
hibited impaired cell growth compared to control cells, as re-
vealed by longer doubling time (1.3 and 1.9 times longer for
HT-1080 and Sal-1, respectively; data not shown), decreased
BrdU incorporation (Figure 2E), and reduced S-phase fraction
(Figure S2A). Moreover, Twist1 knockdown was associated
with induction of acidic b-galactosidase activity (SA-b-gal) (Fig-
ures S2B and S2C), suggesting spontaneous premature senes-
cence, and with reduced tumorigenicity in xenograft models
(Figures 2F and S2D). Twist1 depletion correlated also with en-
hanced sensitivity to serum starvation and UV radiation (Figures
2G, 2H, and S2C). This was paralleled by induction of p53 target
genes (Figure 2I) and was rescued by silencing of p53 (Figures
2G–2I and S2E). No relevant perturbation in cell growth was
observed following Twist1 silencing in sarcoma cells that were
either homozygously deleted (SAOS-2) or mutated (SK-UT-1)
for TP53 or that overexpressed MDM2 (SJSA) (Figure S2A).
Twist1 antagonizes oncogene-induced apoptosis at least in
part by interfering with the ARF/p53 pathway. However, a signif-
icant fraction of sarcomas and sarcoma-derived cell lines
(including HT-1080, Sal-1, MES-SA, VA-ES-BJ, and WE68) are
deficient for INK4a/ARF, and Twist1 can attenuate Myc-induced
apoptosis in p53 wild-type/ARF null U2-OS cells (Figure S2F).
This suggests that Twist1 impinges on p53 also independently
of ARF.
Twist1-Mediated Antagonism of p53 Activity Does Not
Require an Intact Basic Domain or Binding to p300/CBP
To shed light on the mechanisms of Twist-induced destabili-
zation of p53, we characterized Twist1 domains required to
antagonize the p53 response. Twist1 is known to regulate the
transcription of several genes by binding their promoters through
its basic DNA binding domain (Cakouros et al., 2010; Yang et al.,
2010). We therefore investigated whether Twist1 modulated
p53 response through a direct transcriptional mechanism. To
this end, a series of Twist1 mutants defective for DNA binding
(Spicer et al., 1996) (Figure 3A) were assayed for inhibition of
p53-mediated transcription and apoptosis in E1A/Ras MEF
(ER-MEF), which represent a well-defined setting of oncogene-
induced/p53-dependent apoptosis (Lowe et al., 1993). In
these cells, ectopic Twist expression attenuates p53-induced
apoptosis (Maestro et al., 1999), whereas silencing of endoge-
nous Twist1 results in enhanced stress sensitivity (Figures
S3A–S3E). Despite loss of DNA binding activity, Twist1 basic
domain mutants retained ability to protect ER-MEF from p53-
mediated apoptosis (Figures 3B and S3F) and to repress
a p53-responsive promoter (Figure S3G). More importantly,
similar to full-length Twist1, the mutant carrying a deletion of
the whole basic domain (Db) was capable of converting nontu-
morigenic RE-BJ into tumorigenic cells (Figures 3C and S3H).
Taken together, these data indicated that Twist1 could antago-
nize p53 and contribute to cancer development through an
E-box-independent mechanism.
Twist1 has been hypothesized to interfere with p300/CBP-
mediated activation of p53 (Ansieau et al., 2008; Hamamori
et al., 1999; Shiota et al., 2008). To test this hypothesis, we
generated a Twist1 mutant devoid of the major p300/CBP
binding region (D30-60) (Figure 3A). The p300/CBP binding
region overlaps Twist1 nuclear localization signal (NLS), and,
therefore, theD30-60mutant lost nuclear localization (Figure 3D).
To circumvent this problem, an ectopic NLS (KRKK)was inserted
at the N terminus (D30-60NLS). Despite impaired p300 binding,
Twist1 D30-60NLS retained the power of repressing p53-
mediated transcription (Figures S3G–S3I) and promoting cell
survival (Figure 3D). This result demonstrates that the binding
to p300/CBP is dispensable for Twist1-mediated inhibition of
p53. Moreover, the fact that only the mutant expressed in
the nucleus was capable of preventing p53-dependent
apoptosis indicates that Twist1 requires nuclear localization to
antagonize p53.
Twist and p53 Establish Tail-Tail Interaction
that Involves the Twist box and p53 C-Terminal
Regulatory Domain
It has been recently proposed that p53 may interact with the N
terminus of Twist1 (Shiota et al., 2008). We then hypothesized
that Twist1 could inhibit p53 response in sarcomas by directly
targeting p53. Immunoprecipitation of endogenous Twist1 re-
sulted in coprecipitation of endogenous p53 (Figure 4A), indi-
cating that Twist1 does interact with p53 in sarcoma cells. The
interaction is direct, as demonstrated by GST pull-down and
coprecipitation assays using GST-Twist1 and His-p53 recombi-
nant proteins (Figure 4B).
GST pull-down experiments confirmed the suggested weak
interaction between p53 and the very N terminus of Twist1 (Fig-
ure S4A). However, we have shown that the deletion of this
region does not affect the ability of Twist1 to antagonize p53-
dependent transcription and apoptosis (D30-60NSL) (Figures
3D and S3G), ruling out a major biological relevance for this
particular interaction. Instead, we found that p53 binds robustly
to the C terminus of Twist1. In fact, both in vitro and in vivo
(Figures S4A and S4B) coprecipitation experiments indicated
that Twist1 engages a 20-aa stretch, corresponding to the highly
conserved C-terminal region named Twist box (Bialek et al.,
2004), to interact with p53 (Figure 4C).
The specificity of the bindingwas confirmed byGST pull-down
using a Twist box peptide displayed from the active site loop of
thioredoxin (T175-199), implying that this minimal region is
both required and sufficient for p53 interaction. More impor-
tantly, Twist box-defective mutants were impaired in their
ability to antagonize p53-depedent apoptosis (Figure 4D) and
transcription (Figure S3G). This corroborates the relevance of
the Twist box in the inhibition of p53. Intriguingly, this domain
is conserved also in Twist2 and, in fact, Twist2 protected
ER-MEF and bound p53 as efficiently as Twist1 (Figure 4D;
Figure S4C).
Reciprocal mapping experiments revealed that p53 interacts
with Twist through its C-terminal regulatory domain (aa 354–
393) (p53CTD) (Figures 4E and S4D). These results were also
corroborated by in silico prediction of protein:protein interaction.
Docking simulation of human Twist1 and p53 models provided
the best docking score for p53CTD and Twist1 Twist box, with
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a predicted interface of the complex of 980 A˚2 and a highly
significant lowest energy cluster population (187/500 individ-
uals) (Figures 5A and 5B). In agreement with GST pull-down
data, docking simulations ruled out a major role for other regions
of p53 in the interaction with Twist1, including the p53 ‘‘core
domain’’ (Cho et al., 1994) (lowest energy cluster: 55/500 indi-
viduals). The relevance of Twist box in Twist:p53 interaction
was corroborated by the finding that single amino acid substitu-
tions in the Twist box affected the binding in vitro to p53
(Figure 5C).
Twist1 Hinders p53 Phosphorylation at Ser392
Posttranslational modifications of C-terminal residues are
involved in the regulation of p53 activity and stability (Xu,
2003). Intriguingly, in silico docking experiments indicated that
one of the p53 residues involved in the interaction with Twist1
is the highly conserved Ser392 (Ser389 in mouse). In fact, in
the Twist1:p53 complex, Ser392 is directly engaged in hydrogen
bonds with Arg191 and Ala200 of Twist1 and is shielded by the
Twist1 C terminus (Val189-His202) (Figures 5B and 5D).
Phosphorylation of Ser392 has been implicated in the regu-
lation of p53 stability and activity (Cox and Meek, 2010; Hupp
et al., 1992; Kapoor et al., 2000; Sakaguchi et al., 1997; Yap
et al., 2004). Moreover, mice expressing a p53 mutant that
cannot be phosphorylated at Ser389 (S389A) show impaired
p53 response, with increased sensitivity to chemical and UV-
induced carcinogenesis (Bruins et al., 2004; Hoogervorst et al.,
2005).
We then hypothesized that Twist1 may affect p53 by directly
inhibiting Ser392 phosphorylation. Indeed, we found that
silencing of Twist1 was associated with a significant increase
in the fraction of p53 phosphorylated at Ser392 (PSer392).
Conversely, PSer392 was diminished in the cells engineered
to express Twist1 or p53 binding-proficient Twist1 mutants
but was unaffected in the cells expressing Twist box-deleted
mutants (Figures 6A and S5A). Moreover, transient cotransfec-
tion experiments indicated that, under conditions where
ectopic Twist1 efficiently promoted degradation and repressed
transcriptional activity of wild-type p53, Twist1-mediated inhibi-
tion was impaired toward Ser392 mutants of p53 (Figures 6B
Figure 3. Twist1 Inhibits p53 also Independently of E-Box and p300/CBP Binding
(A) A schematic representation of the mouse Twist1 and various mutants. A114P and A117P carry a destabilizing proline into the basic domain (b); Db is a whole
basic-domain deletion mutant; NLS indicates Twist1 nuclear localization signal, bHLH the basic Helix-Loop-Helix domain; and eNLS denotes the ectopic nuclear
localization signal.
(B) Cell viability of ER-MEF engineered as indicated after oncogene-mediated/p53-dependent apoptosis (0.1 mg/ml doxorubicin, 24 and 48 hr). Histograms
indicate the mean percentage of treated/untreated cells, plus SD. Ctrl are control vector-infected cells.
(C) Representative tumor explants from RE-BJ cells engineered to expressMDM2, Twist1, orDb Twist1 (left). The number of tumors generated in a representative
set of injections is reported on the right. Pictures were taken at week 5.
(D) Left: Immunofluorescence of ER-MEF engineered to express the indicated Twist1 myc-tag constructs. Nuclei are stained with DAPI. Scale bar: 50 mm. Right:
Cell viability of ER-MEF engineered as indicated after apoptotic challenge (0.1 mg/ml doxorubicin, 24 and 48 hr). Histograms indicate the mean percentage of
treated/untreated cells, plus SD.
See also Figure S3.
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and S5B). Finally, although it is still unclear what kinase phos-
phorylates Ser392 in vivo, casein kinase 2 (CK2) has been
shown to target Ser392 in vitro (Cox and Meek, 2010), and
we found that in vitro CK2-mediated phosphorylation at
Ser392 was attenuated in the presence of recombinant Twist1
(Figure S5C).
Twist1 failed to significantly affect the acetylation of Lys373
and Lys382 of p53, two residues involved in p53 stabilization
and included in the region of p53 engaged in the interaction
with Twist1 (Figures S5D–S5F). Although we cannot rule out
that Twist1 may alter other posttranscriptional modifications
relevant for p53 activity and stability, our data indicate that
Twist1 attenuates the p53 response at least in part by impinging
on Ser392 phosphorylation. Intriguingly, different from Lys373
and Lys382 acetylation, Ser392 phosphorylation is triggered in
response to oncogene activation, both in human (Figures S5D–
S5F) and mouse fibroblasts (Figure S5G), and this correlates
with p53 induction. In the same cells, oncogene-induced trans-
formation was associated also with increased Twist1 levels
(Figures S5G and S5H). This suggests that the activation of
Twist1 may represent a mechanism elicited by oncogene-chal-
lenged cells to quench p53 response during transformation.
Figure 4. Twist1 and p53 Bind Directly through the C Termini
(A) Cells lysates from HT-1080, SK-UT-1, and ER-MEF were incubated with either Twist1 monoclonal antibody (Twist1) or nonimmune IgG (Mock), immuno-
precipitated, and then blotted for coprecipitated p53 using anti-p53 antibodies. Twist1-negative MCF7 cells were used as a negative control. Input represents
10% of the whole cell lysate prior immunoprecipitation.
(B) Left panel: 35S-labeled in vitro translated p53 (IVT-p53) was incubated with equivalent amounts of GST-Twist1 or GST, used as a negative control. Complexes
were visualized by autoradiography. Right panel: recombinant His-p53 was incubated with equal amounts of glutathione agarose-bound GST or GST-Twist1.
After SDS-PAGE, complexes were detected with anti-GST and anti-His antibodies.
(C) A schematic representation of the mouse Twist and various Twist1 mutants (left) and summary of their ability to interact with p53 based on GST pull-down
experiments (right).
(D) Cell viability of ER-MEF engineered as indicated after apoptotic challenge (0.1 mg/ml doxorubicin, 24 hr and 48 hr). Histograms indicate the mean percentage
viability plus SD.
(E) A schematic representation of human p53 and derivative mutants (left) and summary of their ability to interact with Twist1 based on GST pull-down exper-
iments (right).
See also Figure S4.
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Twist1 Facilitates p53 Degradation by Increasing
the Affinity of p53 for MDM2
Modifications of p53CTD are known to modulate its suscepti-
bility to MDM2-mediated degradation. We therefore sought to
investigate the role of Ser392 in p53 degradation. CHX-chase
experiments in SAOS-2 and p53/ HCT116 cells engineered
to stably express p53 mutants at codon 392 indicated that
p53-S392E, a mutant mimicking constitutive phosphorylation
at Ser392, displayed a longer half-life than did the p53-S392A
phosphorylation-deficient mutant (Figure 6C). On a side note,
we noticed that both Ser392 mutants were more tolerated
compared to p53 WT, suggesting that Ser392 status affects
both p53 turnover and tumor-suppressive activity. Moreover,
the differential stability of Ser392 mutants was easier to appre-
ciate if the constructs were expressed following stable retroviral
infection instead of acute transfection, likely because of trans-
fection-induced stress response.
Intriguingly, the amount of MDM2 coimmunoprecipitated with
p53-S392E was significantly reduced (50%) compared to the
amount bound to the wild-type p53 and p53-S392A (Figure 6D).
This suggests that phosphorylation of Ser392 makes p53 less
prone to binding toMDM2, and hence toMDM2-driven degrada-
tion. In this scenario, by preventing Ser392 phosphorylation,
Twist1 might affect p53:MDM2 association. In agreement with
this hypothesis, we found that the increase in the overall levels
of p53 detected in HT-1080 cells following Twist1 knockdown
correlated with a slight but consistent decrease (30%) in the
amount of p53 complexed to MDM2 (Figures 6E and S5I).
Figure 5. The Twist box Is Necessary for the Interaction with p53
(A) Ribbon representation of the interaction between p53 (red) and Twist1 (blue). The arrow indicates the Twist box:p53 interface.
(B) A summary of the residues of human Twist1 and human p53 involved in their binding, the functional groups of these residues involved in the interaction, and the
distance (in A˚) between the corresponding interacting functional groups as assessed by docking simulation. In mouse Twist1, the region involved in the binding
spans Ile138-His206.
(C) GST or GST-p53 pull-downs of IVT-Twist box or IVT-Twist box carrying the indicated amino acid substitutions.
(D) Magnification of the ribbon representation of Twist box (blue):p53 CTD (red) interaction. The hydrogen bond formed between p53 Ser392 and Twist1 Arg191
and the distance between these two residues in A˚ are indicated in yellow.
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Thus, Twist1 seems to promote p53 degradation by maintaining
p53 in an MDM2-accessible state.
It has been recently shown that, besides the canonical
N-terminal region (Kussie et al., 1996; Lin et al., 1994), p53 binds
MDM2 also with the CTD, and this interaction is hampered by
p53CTD modifications (Poyurovsky et al., 2010). Thus, Twist1
could interfere with this alternative mechanism of MDM2-
mediated degradation of p53. However, an interplay between
Ser392 and Ser15 of p53 has been proposed (Kapoor et al.,
2000), and phosphorylation at Ser15 is well known to inhibit
MDM2 from binding N terminus p53 (Shieh et al., 1997). There-
fore, we investigated a possible cross-talk between these two
serines. We found that p53-S392E displayed a greater extent
of phosphorylation at Ser15 than did p53-S392A (Figure 6F).
Instead, constitutive phosphorylation at Ser15 (S15E) failed to
affect the extent of phosphorylation at Ser392 (Figure S5J).
This suggests a directional control of Ser15 phosphorylation by
Ser392 status. Moreover, modulation of Twist1 expression in
Figure 6. Twist1 Hinders Phosphorylation of p53 at Ser392 and Affects p53:MDM2 Interaction
(A) Immunoblot for p53 phosphorylated at Ser392 (P Ser392) of sarcoma cells silenced for Twist1 expression (left) or engineered to express ectopic Twist1 or
Twist1 mutants (right). Because modulation of Twist1 expression affects p53 expression levels, to better appreciate the effect of Twist1 on Ser392 phosphor-
ylation, samples were unevenly loaded to tentatively equalize the signals for total p53.
(B) Immunoblot of Twist1-negative p53/ HCT116 transfected with wild-type p53 or p53 mutants (4 mg) as indicated together with either myc-Twist1 (Tw) or
empty control vector (Ctr) (20 mg). GFP (1 mg) was included for normalization of transfection efficiency. This result was confirmed on three independent
experiments.
(C) Cycloheximide-chase assays (CHX, 250 mg/ml) in SAOS-2 cells infected with retroviral vectors encoding p53WT, p53 S392E (phospho-mimic), or p53 S392A
(phospho-impaired).
(D) SAOS-2 engineered to express p53 WT, S392A, or S392E p53 were treated with MG132 (10 mM, 8 hr), then were immunoprecipitated for p53. Immunoblots
were probed with anti-MDM2 and -p53 antibodies, and the amount of MDM2 coprecipitated was calculated asMDM2/p53 ratio. This result was confirmed in two
independent experiments.
(E) Twist1-silenced (shTw) and control (shCtr) HT-1080 were treated with MG132 (10 mM, 8 hr), immunoprecipitated for endogenous p53, and then probed for
MDM2 and p53. The amount of MDM2 bound to p53 was calculated as MDM2/p53 ratio. This experiment was done three times with two different p53 antibodies
(DO-1 and CM5).
(F) Immunoblot of p53/ HCT116 engineered to express either S392A or S392E p53, under standard conditions (NT), UV radiation (20 J/m2) or serum starvation
(30 hr).
(G) Immunoblots for p53 phosphorylation at Ser15 and Ser392 in sarcoma cells after modulation of Twist1 expression. GAPDH was used for normalization.
(H) Schematic representation of the proposed mechanisms of Twist1 contribution to oncogene-induced transformation and attenuation of p53 response.
See also Figure S5.
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sarcoma cells correlated with concordant variations in Ser392
and Ser15 phosphorylation (Figure 6G). Thus, besides interfering
with the p53CTD:MDM2 interaction, Twist1 might indirectly
affect also the canonical route of MDM2-mediated p53 degrada-
tion, suggesting the existence of multiple levels of controls of
Twist1 over p53 (Figure 6H).
DISCUSSION
By investigating the role of Twist1 in the context of sarcomas,
this study highlights an alternative mechanism of p53 inacti-
vation and provides evidence that Twist1 promotes MDM2-
mediated degradation of p53 by directly interacting with
its C-terminal regulatory domain and by interfering with key
phosphorylations.
We found that although Twist1 expression pattern in carci-
nomas is compatible with its proposed role inmalignant progres-
sion, the diffuse and strong Twist1 accumulation observed in
sarcomas suggests that Twist1 activation is an intrinsic com-
ponent of the transformed phenotype of tumor cells of mesen-
chymal origin. This hypothesis is supported by the finding that,
in these tumors, Twist1 accumulation often associates with
TWIST1 copy-number gain, a result that is in line with recent
evidence that one of the most frequent copy-number variations
in sarcomas involves the TWIST1 locus (Menghi-Sartorio et al.,
2001; Taylor et al., 2008).
In addition, we found that, in LS, Twist1 overexpression is
mutually exclusive with MDM2 positivity. In LMS, Twist1 accu-
mulation clustered among p53 wild-type tumors, although the
correlation was not statistically significant. This may be in part
due to the small sample size of these clinically rare tumors. On
the other hand, although early studies suggested that TP53
mutation and MDM2 overexpression were mutually exclusive,
subsequent studies have demonstrated that this is not a general
rule. Indeed, overexpression/amplification of MDM2 and TP53
mutation can coexist in the same tumor, likely because both
p53 and MDM2 are provided with functions independent of
each other (Cordon-Cardo et al., 1994; Ito et al., 2011; Manfredi,
2010). Similarly, Twist1 is also provided with p53-independent
functions that may play a role in sarcomagenesis (e.g., inhibition
of differentiation) and might account for Twist1 and MDM2
coexpression observed in six LMS retaining wild-type TP53.
Most evidence linking Twist1 to cancer refers to the ability of
Twist proteins to modulate the expression of target genes,
including ARF, thus affecting p53. This study provides evidence
that Twist1 affects p53 also through an E-box-independent
mechanism. In fact, we found that Twist1 mutants defective for
DNA binding retain the ability to interfere with the p53 response.
This indicates that Twist1 may participate to tumorigenesis and
promote the bypass of p53 failsafe programs apparently
through molecular mechanisms different from those that facili-
tate EMT in carcinomas.
Intriguingly, we found that Twist1 establishes a direct interac-
tion with p53 through the Twist box and that this interaction is
critical for Twist1 inhibition of p53. The Twist box corresponds
to a highly conserved 20-aa stretch at the C terminus of the
protein. Through the Twist box, Twist binds to and inhibits
RunX2 (Bialek et al., 2004), MEF2 (Spicer et al., 1996), ATF4
(Danciu et al., 2012), and RelA (Sosic et al., 2003). This suggests
that the binding via Twist box is a leitmotif in the inhibition exerted
by Twist on other transcription factors. Here, we demonstrate
that Twist employs the Twist box to interact with the CTD
regulatory domain of p53. By binding p53CTD, Twist1 hinders
Ser392 phosphorylation, and this correlates with increased p53
sensitivity to degradation. Although Twist1 failed to significantly
affect Lys373 and Lys382 acetylation, we cannot exclude that,
by interacting with p53CTD, Twist1 may influence other modifi-
cations that affect p53 functions. Nevertheless, the fact that
Ser392 is phosphorylated in response to oncogene activation
and modulates p53 activity and stability corroborates the
concept that Twist1 participates to sarcomagenesis at least in
part by interfering with Ser392-mediated p53 activation.
How may Twist box:p53CTD interaction affect p53 response?
Recently, Prives’s group has demonstrated that, besides the
canonical N terminus, p53 engages also the CTD region to
bind MDM2, and this interaction is hampered by p53CTD
posttranslational modifications (Poyurovsky et al., 2010).
Although the authors addressed the effect of acetylation on
p53CTD:MDM2 complex formation, they argued that other
p53CTD modifications are likely to impinge on this interaction.
By using Ser392 mutants, we collected data suggesting that
Ser392 phosphorylation reduces p53 affinity to MDM2. Thus,
by hindering Ser392 phosphorylation, Twist1 might favor
p53CTD:MDM2 complex formation and hence p53 degradation.
Yet we found that Ser392 status influences also the extent of
phosphorylation at Ser15 that inhibits the interaction between
N terminus p53 and MDM2. Then, by acting on Ser392, Twist1
might in turn impinge on Ser15, thus facilitating also the canon-
ical route of MDM2-mediated degradation of p53.
Finally, in agreement with recent observations (Kogan-Sakin
et al., 2011; Lee and Bar-Sagi, 2010), we found that oncogene-
challenged human and mouse fibroblasts display increased
levels of Twist1. This suggests a scenario where oncogenic
transformation results in the induction of Twist1. In turn, Twist1
promotes the bypass of oncogene-induced p53 safeguard
responses by both inhibiting the ARF/p53 signaling and by
directly interacting with p53 and facilitating its degradation
(Figure 6H).
In conclusion, this study sheds light on the mechanisms of
Twist1-mediated inactivation of p53 and adds another important
piece of information on the role of p53CTD in the regulation of
p53 tumor-suppressive activity. Although focused on sarcomas,
our study proposes a model that might also apply to other tumor
histotypes and provides the proof of principle that targeting
Twist1:p53 interaction may offer additional avenues for the
treatment of tumors.
EXPERIMENTAL PROCEDURES
Immunohistochemistry and FISH
Primary sarcoma samples and corresponding normal tissues were retrieved
from the Treviso General Hospital and the San Raffaele Institute tissue banks,
where they were analyzed with patients’ consent. Specimens were deidenti-
fied before analysis, and the study was approved by the IRB of CRO, Treviso
General Hospital, and San Raffaele Institute. No patient had received radio- or
chemotherapy prior to surgery. Immunohistochemistry was performed on
5-mm sections with the following antibodies: Twist1 (Twist2C1a, Santa Cruz),
Twist 2 (ab6603, Abcam), p53 (DO-7, Labvision), and MDM2 (1F2, Oncogene
Science). FISH was performed following standard protocols on 19 cases for
which frozen material was available.
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TP53 Mutation Analysis
Mutation analysis of TP53 was performed by PCR direct-sequencing on
genomic DNA extracted from paraffin-embedded tissue sections, as previ-
ously described (Dei Tos et al., 1997).
Cells, Constructs, and Protein Expression Analyses
Transfections, retroviral infections, and reporter assays were performed as
previously described (Demontis et al., 2006). Acute silencing of Twist1 was
achieved with ON-TARGETplus SMART pool siRNAs (Dharmacon), according
to the manufacturer’s instructions. Stable silencing of Twist1 was achieved by
retroviral infection of previously published Twist1-specific shRNAs (Ansieau
et al., 2008; Yang et al., 2004). shGFP and shLuciferase (shLuc) were used
as negative controls. Protein lysates were separated by SDS-PAGE and
were transferred onto nitrocellulose membrane (Protran, Whatman). Expres-
sion analyses were performed with Odyssey Infrared (Li-Cor Biosciences)
and Chemidoc (BioRad) Imaging systems, using the antibodies indicated in
Supplemental Experimental Procedures. Immunofluorescence and SA-b-gal
staining were performed as previously described (Di Micco et al., 2006; Seger
et al., 2002). GST pull-downs and in vitro CK2 assay were performed as
described in Supplemental Experimental Procedures.
Apoptosis, BrdU Incorporation, and FACS Analyses
Cell viability was assessed by Trypan blue and Viacount assay (Guava PCA)
and was calculated as mean percentage of cells that survived the apoptotic
stress (1003 viable treated cells/untreated cells). Experiments were done in
triplicate on at least two different retroviral infections. Caspase 3/7 activation
and BrdU incorporation were determined with the Apo-ONE Caspase-3/7
and the BrdU Kits (Promega). FACS analyses were done with the Cytomics
FC 500 (Beckman Coulter).
In Vivo Tumorigenicity Assay
Experiments on animals were performed in accordance with national regula-
tions and approved by the CRO animal ethics committee. RE-BJ cells (5 3
106) stably expressing MDM2, dnp53, shp53, or Twist were subcutaneously
injected into each flank of six-week-old athymic nude mice (Hsd:Athymic
nude-nu, Harlan) as previously described (Di Micco et al., 2006; Seger et al.,
2002) For pRetroSuper-shLuc and pRetroSuper-shTwist HT-1080, 1 3 106
cells were used. Tumor size was monitored weekly. Mice were sacrificed at
week 5. Tumor volume was calculated as 2r3.
Protein Modeling and Docking Simulations
Three-dimensional structure models of Twist1 and p53 were built using the
web server SAM-T08 (Karplus, 2009) and further minimized by simulated an-
nealing using the program CNS (Bru¨nger et al., 1998). Docking calculations
were carried out by the web server ClusPro 2.0 (Comeau et al., 2007).
Statistical Analysis
Data shown are means ± SD of at least three independent experiments.
Comparisons of proportions were performed using two-tailed Fisher’s exact
test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online
at http://dx.doi.org/10.1016/j.ccr.2012.08.003.
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SUPPLEMENTAL DATA 
 
 
Figure S1, related to Figure 1 
(A) Expression levels of endogenous Twist1, Twist2, p53 and MDM2 in the human cell lines used in this study. 
RE-BJ are human primary fibroblasts transformed by the ectopic expression of HRasV12 and E1A. HCT116 
colon carcinoma cells were included as a reference (Ctr). Protein levels were normalized to GAPDH. (B) TP53 
status of the human cell lines used in the study. (C) Expression levels in RE-BJ engineered to express ectopic 
myc-tag Twist1 (Tw1). The blot was probed with an anti-Twist1 antibody. End Twist1 indicates the endogenous 
Twist1 protein. (D) Expression levels in RE-BJ engineered to express ectopic untagged Twist2 (Tw2). The blot 
was probed with an anti-Twist2 antibody. Ctr indicates empty vector-infected RE-BJ cells.   
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Table S1. Twist1 immunoreactivity in human sarcomas and normal mesenchymal tissues, 
related to Figure 1 
 Sample Positive cases / 
Total cases analyzed 
Normal myocytes Negative 
Normal chondrocytes Negative 
Normal osteocytes Negative 
Normal adipocytes Negative 
Normal visceral fibroblasts Negative 
Normal dermal fibroblasts Positive * 
Chondrosarcoma 2/3 
Ewing sarcoma 4/9 
Fibrous Solitary Tumors 5/5 
GIST (Gastro-Intestinal Stromal Tumors) 0/4 
Leiomyosarcoma 12/26 
Liposarcoma 15/24 
MPNST (Malignant Peripheral Nerve Sheath Tumor) 8/8 
Myxofibrosarcoma 2/5 
Osteosarcoma 1/2 
Pleomorfic sarcoma 9/13 
Rhabdomyosarcoma  12/20 
Synovial sarcoma 18/27 
 
Total 
 
88/146 (60.3 %) 
 
* Scattered reactive cells 
4 
 
Table S2. TWIST1 copy-number gain in human sarcomas, related to Figure 1 
Histology 
p53 
IHC 
MDM2 
IHC 
TWIST1 
FISH 
(TWIST1 to centromere 7 ratio) 
Pleomorphic liposarcoma +++ - Normal 
Pleomorphic liposarcoma + - Normal 
Pleomorphic liposarcoma - + Normal 
Dedifferentiated liposarcoma + ++ Normal 
Dedifferentiated liposarcoma - ++ Normal 
Leiomyosarcoma - - Amplification (10/2) 
Pleomorphic rhabdomyosarcoma - - Chromosome gain (10/10) 
Pleomorphic sarcoma  - + Chromosome gain (4/4) 
Pleomorphic sarcoma + - Chromosome gain (8/8) 
Pleomorphic sarcoma + - Chromosome gain (8/8) 
Pleomorphic sarcoma - - Amplification (12/4) 
Pleomorphic sarcoma - - Chromosome gain (5/5) 
Pleomorphic sarcoma ++ - Normal 
Pleomorphic sarcoma  +++ - Normal 
Pleomorphic sarcoma + + Normal 
Pleomorphic sarcoma + - Chromosome gain (6/6) 
Pleomorphic sarcoma  - + Normal 
MPNST ++ - Normal 
MPNST - - Chromosome gain (4/4) 
        
Amplification/Gain     9/19 Twist1-positive cases  
 
FISH analysis for TWIST1 copy-number gain/amplification on a selected series of frozen sarcomas at different 
stages, previously tested positive for Twist1 overexpression. The table shows the immunoreactivity for p53 and 
MDM2 antibodies, along with the result of FISH analysis (TWIST1 to centromere 7 ratio). 
 
 
 
Table S3. Twist1 immunoreactivity in human carcinomas, related to Figure 1 
Sample Positive cases / 
Total cases analyzed 
Breast carcinoma 62/195 (32%) 
Colorectal carcinoma 7/53 (13%) 
Prostate carcinoma 6/21 (28%) 
Lung carcinoma 6/48 (12%) 
Total 81/317(26%) 
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Table S4. Twist1 inversely correlates with TP53 mutation in Leiomyosarcomas,  
related to Figure 1 
NR SITE 
TP53 
status 
IHC 
p53 MDM2 Twist1 Twist2 
5 vena cava R158H ++ - - - 
13 uterus C275F +++ - - - 
6 stomach R175H +++ - - - 
2 uterus R248Q +++ - - - 
34 vena cava V272M +++ - - - 
22 soft tissue, upper limb Y220C +++ - - - 
36 soft tissue, lower limb Y234D +++ - + - 
17 uterus Y205F +++ ++ ++ ++ 
35 soft tissue, upper limb WT +++ ++ ++ - 
31 soft tissue, left leg WT +++ + ++ - 
3 bladder WT +++ - ++ - 
26 uterus WT ++ +++ - - 
10 uterus WT ++ + +++ ++ 
7 uterus WT ++ + - - 
15 soft tissue, upper limb WT + - - - 
1 uterus WT + - - - 
20 soft tissue, lower limb WT + - - - 
28 soft tissue, retroperitoneum WT + - - - 
30 soft tissue, retroperitoneum WT + - - - 
38 vena cava WT + - - - 
18 soft tissue, lower limb WT + ++ +++ - 
37 soft tissue, lower limb WT + - ++ - 
25 cutis WT - + +++ ++ 
21 soft tissue, lower limb WT - - +++ - 
27 soft tissue, retroperitoneum WT - - ++ - 
29 soft tissue, retroperitoneum WT - - ++ - 
24 colon WT - - ++ - 
19 uterus WT - - ++ - 
33 soft tissue, left leg WT - - ++ - 
4 testis WT - - ++ - 
11 uterus WT - - + - 
12 uterus WT - - - - 
9 uterus WT - - - - 
8 soft tissue, retroperitoneum WT - - - - 
32 soft tissue, retroperitoneum WT - - - - 
 
IHC score 
+++ Diffuse, > 50% positive nuclei 
++ Patchy, 25-50% positivity 
+ Focal, 10-25% positivity 
- Negative, < 10% positivity 
 
Two-tailed Fisher’s exact test:  TP53 mutation vs Twist1 overexpression, p= 0.10 
    TP53 mutation vs MDM2 positivity, p=0.65 
 
 
TP53 mutation and immunohistochemical analysis of p53, MDM2, Twist1 and Twist2 expression in a 
consecutive series of 35 primary, early-stage Leiomyosarcomas 
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Figure S2, related to Figure 2  
(A) Cell cycle FACS analyses in a series of representative sarcoma cell lines after depletion of Twist1 
expression by either shRNA or siRNA. 
(B) SA--gal staining in Sal-1 cells depleted for Twist1 expression (shTw) under standard growth condition. 
Control (shCtr) are shGFP-infected cells. Scale bar: 50 µm. (C) HT-1080 engineered to express the shRNAs 
indicated (shCtr, shTw, shp53) were seeded overnight and then either UV irradiated (20 J/m
2
) or shifted to 
serum-free medium. Photographs were taken at 24 and 72 hr post-stress induction, respectively. SA--gal 
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staining was performed after growth factor deprivation (48 hr). Scale bar: 100 µm. (D) Immunoblot for Twist1 
expression in a panel of xenograft tumors from HT-1080 engineered to express either shCtr or shTwist1. T1-T4 
are tumors arising from shTwist1 HT-1080 cells, C1-C3 are shCtr HT-1080-derived tumors. (E) Immunoblot of 
HT-1080 engineered to express either pRetroSuper-Hygro shGFP or shTwist1 (shTw), subsequently super-
infected with pRetroSuper-Neo encoding either shLuc or shp53. (F) U2-OS MycER cells were infected with 
pLPC-Twist1 (Tw) or pLPC-GFP control vector (Ctr). After selection, cells were plated at 50% confluency, serum 
starved for 48 hr, then treated with Tamoxifen (200 nM in ethanol) to induce Myc protein (Myc ON). Control cells 
were treated with an equal amount of ethanol (Myc OFF). Photographs were taken at day 6. Relative cell 
survival (% of Tamoxifen-treated vs ethanol-treated viable cells) +/- SD is indicated. The right panel shows the 
immunoblot for ectopic myc-tag Twist1. GAPDH was used as a loading control. Scale bar: 100 µm. 
 
  
8 
 
 
 
Figure S3, related to Figure 3 
(A) p53-proficient (p53
+/+
) and p53 null (p53
-/-
) E1A/Ras-transformed MEF (ER-MEF) were used to assess the 
role of Twist1 in oncogene-induced/p53-mediated apoptosis under two different stress conditions (Left: 
Doxorubicin 0,1 g/ml, 24 hr; Right: serum starvation, 48 hr). Histograms represent mean values plus SD. (B) 
Immunoblot for ectopic (ect.) and endogenous (end.) Twist1 expression in p53
+/+
 and p53
-/-
 ER-MEF. GAPDH 
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was used as a loading control. (C) Immunoblot for p53, p21 and Bax in p53-proficient ER-MEF engineered to 
express ectopic Twist1. (D) Expression levels of endogenous Twist1, Twist2 and p53 in p53
+/+
 and p53
-/-
 ER-
MEF. The asterisk (denotes an aspecific band detected by the CM5 anti-p53 antibody in p53
-/-
 MEF. (E) p53 
proficient ER-MEF were transiently transfected with either mouse-Twist1 specific siRNAs (siTw) or a non-
targeting siRNA pool as a control (siCtr) (Dharmacon). Cell viability was assessed by Trypan blue exclusion after 
serum starvation (48 hr). Histograms represent mean values plus SD. The lower panel shows Twist1 expression 
in siCtr and siTw cells. (F) Expression levels of ectopic Twist2, Twist1 and Twist1 mutants in p53
+/+
 ER-MEF. 
The 114X mutant was fused in frame to GFP to increase its stability. (G) Reporter assay quantifying the effect of 
Twist1 on p53-dependent transcription. U2-OS cells were transfected with 1 µg PG13-Luc (p53-reponsive 
reporter), 100 ng Renilla (pRLCMV) and either 1.2 µg pCS2 empty vector (Ctr) or increasing amounts (0.3, 0.6, 
1.2 µg) of the  Twist1 mutants indicated. Dual Luciferase Assay (Promega) was performed 48 hr-post 
transfection. Promoter activity values are expressed as Relative Luciferase Units (RLU) using Renilla expression 
for internal normalization. Experiments were done three times in triplicate. The histograms represent mean 
values plus SD of a representative experiment. Expression levels of the transfected Twist1 constructs are shown 
in the lower panel. (H) Immunoblot showing the expression levels of ectopic Twist1 and b Twist1 mutant in RE-
BJ cells. (I) GST pull-down assay using GST-Twist1 N-terminus mutants and IVT-p300.  
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Figure S4, related to Figure 4  
(A) Left panel: GST pull-down assay using IVT-Twist1 N-terminus mutants and GST-p53 under mild-stringency 
conditions. Right panel: GST pull-down assay using IVT-Twist1 mutants and GST-p53 under high-stringency 
conditions. Lower panels show 10% input of the reaction. (B) Co-immunoprecipitation of ectopically expressed 
Twist1 mutants and endogenous p53. pCS2-myc Twist1 full length and mutants were transfected into U2-OS 
cells. Cell lysates were immunoprecipitated with DO-1 anti-p53 antibody (IP), followed by immunoblot with an 
anti myc-tag antibody. Inputs (10% total cell lysates prior immunoprecipitation) are shown in the lower panel. (C) 
GST pull-down assays using IVT-Twist2 and GST-p53 under high-stringency conditions. (D) GST pull-down 
assay using IVT-p53 and GST-Twist1. Right panel shows 10% input of the reaction. 
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Figure S5, related to Figure 6 
(A) Immunoblots for p53 of ER-MEF transduced with the indicated Twist1 mutants. (B) Reporter assay 
quantifying the effect of Twist1 on p53-dependent transcription driven by p53 mutants for Ser392. p53
-/-
 HCT116 
cells were transfected in 6-well plates with 0.4 µg of pCDNA3 vectors encoding the p53 alleles indicated (wild-
12 
 
type, S392E or S392A) in the presence of 0.4 µg PG13-Luc (p53-reponsive reporter), 0.1 µg Renilla pRLCMV 
reporter (for internal normalization) and 3.2 µg of either pCS2 empty vector (Ctr) or pCS2-myc Twist1. Dual 
Luciferase Assay (Promega) was performed 48 hr post-transfection. Promoter activity values are expressed as 
Relative Luciferase Units (RLU) using empty vector-transfected cells (Ctr) as a reference (100%) for each p53 
allele. Experiments were done three times in triplicate. The histograms represent mean values plus SD of a 
representative experiment. (C) Casein kinase 2 (CK2) assay on recombinant p53. GST-only or GST-Twist1 
(0.25, 0.5, 1.0 µg) were incubated together with recombinant His-p53 in the presence of CK2. Reactions were 
resolved by SDS-PAGE and then probed with anti-phospho Ser392, anti-p53 and anti-GST antibodies, 
consecutively.  
(D-F) Immunoblot for p53 phosphorylation at Ser392 (D) and acetylation at Lys382 (E) and Lys373 (F) of human 
primary fibroblasts (BJ) and sarcomas cell lines engineered as indicated. TSA/Doxorubicin–treated MCF7 were 
used as a positive control (+) for acetylated p53. Ratios represent the amount of p53 modified at the residue 
indicated over total p53.  
(G-H) Immunoblot displaying Twist1 induction in p53
+/+
 and p53
-/-
 MEF (G), and in human BJ fibroblasts (H) 
following ectopic expression of the indicated oncogenes. Ctr are empty vectors-infected cells. This results was 
confirmed in 3 independent infections. The asterisk (denotes an aspecific band detected by the CM5 anti-p53 
antibody in p53
-/-
 MEF. 
(I) Twist1-silenced HT-1080 were first treated with the proteasome inhibitor MG132 (10 µM, 8 hr), then 
immunoprecipitated for endogenous p53. Immunocomplexes were separated by SDS-PAGE and the blots were 
probed for MDM2 and p53. Different from Figure 6F, in this panel immunoprecipitated lysates were unevenly 
loaded to tentatively normalize for total p53, to allow a better appreciation of the effect of Twist1 depletion on 
MDM2:p53 interaction. (J) Immunoblot of p53
-/-
 HCT116 engineered to express either p53 wild-type, a Ser15 
phospho-deficient (S15A) or a phospho-mimic (S15E) mutant, under standard culture conditions (NT), UV 
radiation (20J/m2) or growth factor deprivation (30 hr).  
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Immunohistochemistry and FISH 
Primary sarcoma samples and corresponding normal tissues were retrieved from the tissue banks of the 
Treviso General Hospital and the San Raffaele Scientific Institute in Milan, where they were analyzed with 
patients’ consent. None of the patients had received radio- or chemo-therapy prior surgery. Specimens, obtained 
in accordance with the Institutional Review Boards of the CRO, San Raffaele Institute and Treviso General 
Hospital, were deidentified before analysis, thus qualifying for exemption from human subjects statements. 
Immunohistochemistry was performed on 5-µm sections using an automatic immunostainer (Bond 
System, Leica Microsystems). A non-biotin detection system (Bond Polymer Refine, Leica Microsystems) and 
diaminobenzidine development were employed. Heat-induced antigen retrieval was performed using Tris-EDTA 
buffer (pH 9.0) in a water bath at 95°C for 30 min. 
The antibodies used were: Twist1 (Twist2C1a, Santa Cruz), Twist 2 (ab6603, Abcam), p53 (DO-7, 
Labvision), MDM2 (1F2 , Oncogene Science). Twist1 and Twist2 antibodies were first validated for specificity by 
immunohistochemistry on mouse embryo sections, and by immunoblot on recombinant GST-hTwist1, GST-
hTwist2 and on cells ectopically expressing hTwist1 and hTwist2. No cross reactivity was observed. 
Fluorescence In Situ Hybridization (FISH) was carried out according to standard protocols on samples 
for which frozen material was available. The BAC clone RP11-960P19 (Invitrogen) mapping on chromosome 
7p21 (chr7:19,058,477-19,247,823) was labelled with SpectrumOrange by Nick Translation labelling Kit (Abbott 
Molecular). Chromosome localization (7p21) was confirmed on metaphase spreads from normal peripheral 
lymphocytes. The inclusion of the TWIST1 locus in the clone was confirmed by PCR-direct sequencing. A 
centromere 7 probe (Aquarius, Cytocell) was used for normalization. FISH was performed on frozen sections 
utilizing Nikon Eclipse 90i microscope and Genikon Software (Nikon). One hundred interphase nuclei were 
analyzed per experiment. 
 
TP53 mutation analysis  
 Mutation analysis of TP53 was performed by PCR direct-sequencing on genomic DNA extracted from 
paraffin-embedded tissue sections as previously described (Dei Tos et al., 1997). 
 
Cell culture, transfections and retroviral infections 
E1A/Ras transformed mouse embryo fibroblasts (p53
+/+
 and p53
-/-
 ER-MEF) were kindly provided by 
S.W. Lowe (MSK Cancer Center, New York), p53
-/-
 MEF and p53
-/-
; Mdm2
-/-
 double null MEF by G. Lozano (MD 
Anderson, Huston), HCT116 and p53
-/-
 HCT116 by B. Vogelstein (Sidney Kimmel Cancer Center, Baltimore), 
U2-OS Myc-ER by M. Eilers (University of Wurzburg); the Ewing’ s sarcoma cell lines Sal1 and WE-68 were a 
kind gift from G. Hamilton (University of Vienna) and F. Van Valen (University of Munster), respectively. HT-1080 
(fibrosarcoma), SK-UT-1 (leiomyosarcoma), SAOS-2 and U2-OS (osteosarcoma), MES-SA (undifferentiated 
Mullerian uterine sarcoma), SJSA (Bone sarcoma), BJ (human primary fibroblasts) were from American Type 
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Culture Collection (ATCC). VA-ES-BJ (epithelioid sarcoma) were from ICLC (Genova). The human breast 
carcinomas MCF-7 cells, used as a negative control for Twist1 expression, were from ATCC. 
All cell lines listed above were maintained in a humidified incubator with 5% CO2 and propagated in 
DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS), with the exception of Sal1, WE-68 
and SJSA which were grown in RPMI plus 10% FBS. 
BJ and h-Tert-immortalized BJ were grown in Advanced-MEM plus 10% FBS and non-essential amino 
acids. 
Transfections, retroviral infections and reporter assays using the PG13-Luc plasmid (which carries the 
firefly luciferase gene under the control of 13 p53-responsive elements) were as previously described (Demontis 
et al., 2006; Maestro et al., 1999). 
 
Plasmids 
pCS2 6xmyc-Twist1 full length, Δb and R114P mutants, containing 6Xmyc-tag at the N-terminus of 
mouse Twist1 cDNA, were a kind gift of A. Lassar (Spicer et al., 1996). All the other pCS2 myc-tag Twist 
mutants were obtained by site-directed mutagenesis (QuikChange
TM
 Site Directed Mutagenesis Kit, Stratagene) 
and checked by sequencing. pBabe myc-Twist constructs were obtained by subcloning myc-Twist wild-type and 
mutant cDNAs from pCS2 as BamHI/SnaBI fragments into pBabe Puro (BamHI/SnaBI). pLPC and MarxIVHygro 
myc-Twist constructs were obtained by subcloning myc-Twist from pBabe (as BamHI/ EcoRI fragment) into 
pLPC and MarxIVHygro (BamHI/EcoRI). Twist2 was cloned into pCDNA3 and pLPC. Twist proteins were 
obtained by subcloning Twist cDNAs into pGEX-KG vector (GE Healthcare Life Science). Twist T175-199 and 
p53 T354-393 were generated by subcloning the indicated peptide regions as a fusion protein with the 
thioredoxin active-site loop (T) in the pCDNA3 HA TNV vector, a generous gift of G. Del Sal (University of 
Trieste, Italy). Human Twist1 cDNA was kindly supplied by F. Perrin-Schmitt (Institut National de la Santé et de 
la Recherche Médicale, Strasbourg, France) and subcloned into pCDNA3. pWZL neo E1A, pWZL Hygro 
HRasVal12, pLPC MDM2, pLPC dnp53 (H175), pRetroSuper shp53, pLPC eGFP, pBABE Zeo h-Tert were 
previously described (Di Micco et al.,  2006; Seger et al., 2002). pCDNA3 p53 mutants (299X, 256-393 and 294-
393) and pRSETB-Hisp53 were from G. Del Sal (University of Trieste, Italy). p53 mutants at Ser392 (S392A and 
S392E) were generated by site-directed mutagenesis from pCDNA3 hp53 and pLPC hp53 encoding wild type 
p53. pDNA3 p53 WT, S392A, S392E and pCS3-myc eGFP were used to assess the effect of myc-tag Twist1 on 
ectopic p53 levels. PG13-luc p53-responsive reporter was kindly provided by B. Vogelstein (Sidney Kimmel 
Comprehensive Cancer Center, Baltimore). Acute silencing of Twist1 was performed by transfecting a mix of 
four either human or mouse Twist1-specific siRNAs (ON-TARGETplus SMART pool Dharmacon), using a Non-
targeting Pool as a control, according to the manufacturer’s instructions. Stable silencing of Twist1 was achieved 
by retroviral infection of a validated Twist1-specific shRNA (shTwist1A and shTwist1B) cloned in pRetroSuper 
(Ansieau et al., 2008; Yang et al., 2004). Data were confirmed with both constructs. pRetroSuper-shGFP and 
shLuc were used as negative controls. 
 
Antibodies and protein expression analyses 
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Protein cell lysates were generated using RIPA buffer in the presence of protease and phosphatase 
inhibitors. Tumor protein extraction was performed using a Qiagen Tissuer Lyser (Qiagen). Protein lysates were 
separated by SDS-PAGE and transferred onto nitrocellulose membrane (Protran, Whatman). The antibodies 
used in this study were: mouse monoclonal anti-p53 (DO1, Santa Cruz), rabbit polyclonal anti-p53 (CM5, 
Calbiochem) anti-Twist1 (Twist2C1a, Santa Cruz), anti-myc (9E10, Oncogene Science), anti-polyHistidine 
(Clone HIS-1, Sigma), anti-E1A (M58 and M73, Abcam), anti-H-Ras (OP-23, Oncogene Science), anti-MDM2 
(2A10, Oncogene Science), rabbit polyclonal anti-Bax (#2772, Cell signaling), anti-Puma (#4976, Cell signaling), 
anti-p21 (#70, BD Transduction Laboratories ), anti-FLAG (F3165, Sigma), rabbit polyclonal anti-phospho 
Ser392 p53 (ab3257 and ab59207, Abcam), rabbit polyclonal anti-phospho Ser15 p53 (#9284, Cell signaling), 
anti-GST (#2622, Cell signaling). Mouse monoclonal anti-γ-tubulin (Clone GTU-88, Sigma) or anti-GAPDH 
(MAB374, Chemicon International) were used for normalization. For immunohistochemistry the antibodies used 
were: Twist1 (Twist2C1a, Santa Cruz), Twist 2 (ab6603, Abcam), p53 (DO-7, Labvision) and MDM2 (1F2, 
Oncogene Science). 
Expression analyses were performed with either the Odyssey Infrared (Li-Cor Biosciences) or the 
Chemidoc (BioRad) Imaging system. Integrated intensities of the bands were measured using the dedicated 
application softwares. 
Co-immunoprecipitation assays were performed on both naive and transfected cells, 48 hr post-
transfection. Three million cells were lysed in 1 ml Protein Lysis Buffer (PLB: 20mM Tris-Cl pH 8.0, 150mM 
NaCl, 5mM MgCl2, 0.2 mM EDTA and 0.1% Nonidet-P40) supplemented with protease inhibitors and 1mM 
PMSF, pre-cleared with 100 µl of 50% slurry protein G-Sepharose 4 Fast Flow (GE Healthcare Bio-Sciences AB) 
and then incubated for 3 hr at 4°C with 1 µg of the appropriate MoAb previously conjugated with Protein G-
Sepharose. After incubation, beads were washed, resuspended in 20 µl of 2XLaemmli buffer and boiled. 
Proteins were separated by SDS-PAGE and analyzed by Western blotting with the indicated antibodies. 
Direct interaction between recombinant proteins was determined by combining 5 µg of His-p53 bound to the Ni-
NTA agarose resin (Qiagen) together with 15 µg of either GST-Twist or GST-only recombinant protein in PLB for 
2 hr at 4 °C. After incubation, beads were extensively washed, then resolved by SDS-PAGE. 
For GST pull-down experiments, indicated proteins were in vitro translated (IVT) with [
35
S]-methionine 
(Perkin Elmer) using the TNT System (Promega). IVT-proteins were incubated together with 5 µg of the 
indicated bacterially expressed GST-fusion protein in PLB plus 30 µl of 50% slurry Glutathione Sepharose Resin 
(GE Healthcare). The resin was incubated for 2 hr at 4°C, then extensively washed. Bound proteins were 
separated by SDS-PAGE. Gels were stained with Coomassie Brilliant Blue, dried and exposed to X-ray films 
(Kodak). For detecting the binding between N-terminus Twist1 and p53 milder binding conditions were used 
(20mM Tris-Cl pH 8.0, 100mM NaCl, 5mM MgCl2, 0.2 mM EDTA and 0.02% Nonidet-P40). 
For CHX chase experiments, cells were treated with CHX (100 μg/ml for HT-1080, VA-ES-BJ, p53
-/-
 
HCT116; 250 μg/ml for SAOS-2), harvested at time 0, 15min, 30min, 1 hr, 2 hr, 4 hr, 6 hr, lysed and analyzed by 
SDS-PAGE. 
Immunoprecipitation of MDM2 and p53 complexes was performed in the presence of the proteasome 
inhibitor MG132 (10 μM, 8 hr) (Sigma Aldrich). 
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Immunofluorescence and SA-ß-gal staining 
Immunofluorescence was performed by transfecting U2-OS cells with pCS2 myc-Twist1 (wild-type and 
mutants) as previously described (Di Micco et al., 2006). Primary antibody was a mouse monoclonal anti-myc 
(9E10, Oncogene Science), secondary antibody was a fluorescein horse anti-mouse IgG (Vector Laboratories). 
Nuclei were counterstained with DAPI. 
 Premature senescence was detected by SA-β-gal staining as previously described (Seger et al., 2002). 
 
Apoptosis, BrdU incorporation and cell cycle FACS analyses 
A well established model of oncogene-induced p53-mediated apoptosis (E1A/Ras MEF, ER-MEF) (Lowe 
et al., 1993) was used for apoptotic assays. Serum starvation and mild genotoxic stress (0.1 µg/ml Doxorubicin) 
were used to trigger apoptosis, as previously described (Demontis et al., 2006; Maestro et al., 1999).  
Cell viability was assessed by Trypan blue assay. Survival rates were confirmed with the Viacount assay 
read on a Guava PCA Instrument. Experiments were done in triplicates on at least two different retroviral 
infections. Histograms indicate the mean percentage of cells that survived the apoptotic stress (100X treated 
viable cells/untreated viable cells), plus SD. Caspase 3/7 activation was determined using the Apo-ONE 
Homogeneous Caspase-3/7 Assay (Promega). 
BrdU (bromodeoxyuridine) incorporation was assessed using the Promega BrdU Kit (Promega). 
Readings were performed at the appropriate wavelength using a Tecan Genius Reader. 
Cell cycle FACS analyses were performed using a Cytomics FC 500 Beckman Coulter and the WinCycle 
software (Phoenix Flow Systems, San Diego, CA). 
 
In vivo tumorigenicity assay 
Experiments on animals were performed in accordance with national regulations and were approved by 
the CRO ethical committee for animal experimentations. All experiments conform to the relevant regulatory 
standards. 
hTert-immortalized (pBabeZeo-hTERT) BJ human primary fibroblasts were co-infected with pWZLhygro-
HRASV12 and pWZLneo-E1A. After drug selection, cells were further infected with a pLPC vector encoding 
either MDM2, dnp53 (H175), shp53 or Twist constructs. pLPC empty vector was used as a control. After 
puromycin selection, 5 x10
6
 cells were subcutaneously injected into each flank of six-week-old athymic nude 
mice (Hsd:Athymic nude-nu, Harlan) as previously described (Seger et al., 2002). For pRetroSuper-shLuc and 
pRetroSuper-shTwist HT-1080, 1 x10
6
 cells were used.  
Tumor size was monitored weekly. Mice were sacrificed at week 5. Tumor volume was calculated as 2r
3
. 
 
 
Protein modeling and docking simulations 
Three dimensional model structure of both Twist1 and p53 were built using the web server SAM-T08 
(Karplus et al., 2009) and further minimized by simulated annealing using the program CNS (Brunger et al., 
1998). Docking calculations were carried out by the web server ClusPro2.0 (Comeau et al., 2007) through a 
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systematic, rigid-body search of the first molecule translated and rotated about the second. The intermolecular 
energies for all configurations generated by this search were calculated as the sum of electrostatic and Van der 
Waals energies. After choosing the lowest energy solutions, these were clustered together and the lowest-
energy individual from the most populated cluster was considered as a successful candidate. In our case, 
clusterization was particularly favourable being the lowest-energy cluster populated by 187 individual while the 
second lower by 85. We also checked the likelihood of an interaction between Twist1 and the DNA-binding 
“core” region of p53. To this end, to perform the docking calculation, as a receptor, we used the crystallographic 
structure of p53 “core domain” (Cho et al., 1994) [PDB code 1TUP ]. After editing the coordinate file to delete 
water and DNA molecules, we run ClusPro2.0 using the same parametrization as previously described. In this 
case, the lowest energy cluster was populated by 55 individual being the second and the third lower populated 
by 54 and 50 individual respectively, thus indicating an unfavourable conformation for p53 region chosen. 
 
In vitro CK2 assay 
 Purified His-p53 (0.025 µg) was pre-incubated with either GST-Twist box or GST only (0.25, 0.5, 1 µg) 
for 1 hr at 4°C in 40 µl of Kinase buffer (Biolabs) to allow protein interaction. After pre-incubation, kinase reaction 
was performed for 1 hr at 30°C in the presence of 0.025 Units of purified CK2 (Biolabs) and terminated by 
addition of sample buffer. Proteins were then separated by SDS-PAGE and analyzed by western blot using anti-
Ser392, anti-p53 and anti-GST antibodies. 
 
Statistical analysis 
Data shown are means SD of at least three independent experiments. Comparisons of proportions 
were performed with a two-tailed Fisher’s exact test. 
